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Abstract 
 
Characterization of the RNA transcriptome by next-generation sequencing can 
produce an unprecedented yield of information that provides novel biologic insights.  I 
describe four approaches for sequencing different aspects of the transcriptome and 
provide computational tools to analyze the resulting data. Methods that query the 
dynamic range of gene expression, low expressing transcripts, micro RNA levels, and 
start-site usage of transcripts are described.  
Assessing changes in start-site usage can reveal major regulatory events that 
may be difficult to identify by standard gene expression analysis. By optimizing cDNA 
library construction steps to enhance for sequencing from 5’ ends of transcripts, I 
developed a robust protocol to measure start-site usage of transcripts with high 
sensitivity. To identify genome-wide start-site usage changes between different 
biological specimens, I developed a computational approach that queries the 
distribution of reads at the 5’ ends.  This methodology is denoted as 5’RNAseq.  
Genome-wide 5’RNAseq of cardiac tissues from a mouse model of hypertrophic 
cardiomyopathy (HCM) identified Four-and-a-half LIM domains protein 1 (Fhl1) as the 
gene that exhibits the most marked change in start-site usage. Analysis of the specific 
cell populations in the heart revealed that the increased expression of Fhl1 and change 
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in 5’ regulation occurs in myocytes that become engulfed in fibrosis during disease 
progression.  Further analyses of human ventricular specimens from subjects with a 
variety of cardiovascular pathologies revealed the identical Fhl1 start-site switch occurs 
in both primary and secondary cardiomyopathies.   
Genetic ablation of Fhl1 in the mouse model of HCM resulted in markedly 
increased hypertrophy and histopathologic remodeling, indicating that Fhl1 acts as an 
adaptive modifier of HCM. This result contrasts with data from an earlier report that 
suggest that Fhl1 attenuates hypertrophy caused by pressure overload, and suggests 
that Fhl1 may be implicated in distinct responses to these different cardiac pathologies. 
As Fhl1 is encoded on chromosome X, the potentially protective role of Fhl1 in HCM 
may account for more severe clinical manifestations and outcomes in male patients with 
HCM and may provide novel therapeutic avenues to limit disease. More broadly, this 
work provides new tools that can be used to analyze transcriptomic information. 
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Chapter 1. Introduction: 
Improving human health globally is one of the greatest achievable challenges of 
our time. A better understanding of human biology and disease enables development of 
medical treatments. Further improvement of public health relies on continued 
commitment to improving healthcare and strengthening of interdisciplinary research 
programs aiming to better understand human disease. 
Accelerating advancements in biology and engineering offer new avenues to 
treat heart disease by illuminating the complex physiology of the heart, as well as 
elucidating the numerous causes of its failure. Despite improvements in care of heart 
disorders, heart disease remains the leading cause of death worldwide1. In the United 
States alone, heart disease was responsible for 600,000 deaths (approximately a 
quarter of total deaths) in 2011 [1]. Heart failure burdens sufferers with progressive 
disability and early death.  
The heart is fundamentally a pump powered by the contraction of muscle tissue. 
The heart’s defining function, the heartbeat, is felt throughout the entire body and is the 
life-defining characteristic of most animals. Survival requires that this muscle functions 
continuously without pause for the many decades of life. Cardiomyopathy is the 
dysfunction of this cardiac muscle tissue. Understanding the physiology of the heart and 
the multiple determinants of heart disease is key to finding new ways to effectively treat 
heart diseases. 
Cardiomyopathies can be divided into two categories: primary and secondary. 
Primary cardiomyopathies are confined to the heart. Secondary cardiomyopathies are 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 World Health Organization 
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due to a systemic disorder. While improved understanding of cardiac physiology has 
illuminated the general processes underlying most cardiomyopathies, the mechanistic 
basis of the most common primary cardiomyopathy, hypertrophic cardiomyopathy 
(HCM), remains elusive. This dissertation focuses on HCM, investigating its pathology 
and examining its relationship to other cardiomyopathies. Other cardiomyopathies are 
discussed in various extents throughout: discussion of HCM and primary 
cardiomyopathies is presented in Chapters 1, 5 and 6, whereas secondary 
cardiomyopathies are discussed in Chapters 5 and 6. 
 
Inherited Cardiomyopathies 
Inherited cardiomyopathies are marked by heterogeneity, in that the disease 
clinically manifests uniquely from person to person. Nevertheless, major clinical 
hallmarks can serve to classify cardiomyopathies into the following distinct conditions: 
hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), restrictive 
cardiomyopathy (RCM), arrthythmogenic right ventricular cardiomyopathy (ARVC), 
catecholaminergic polymorphic ventricular tachycardia (CPVT), and left ventricular 
noncompaction [2, 3, 4]. Precisely defining causal mutations will help to further our 
understanding of the genetics and pathophysiology of these diseases. 
HCM is characterized by myocardial wall thickening, impaired relaxation of the 
muscle (diastolic dysfunction) and arrthythmias. It is a common disease, affecting 1:500 
individuals [5, 6].  
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Figure 1.1. Overlap between genes with identified causal mutations for inherited 
cardiomyopathies. Reprinted from Watkins et al., 2011 [2] with permission from the 
copyright holder (Massachusetts Medical Society). 
 
DCM is characterized by dysfunction during systole, dilatation and thinning of the 
myocardial wall, and a general impairment of the ability of the muscle to pump blood. 
Affecting at least 1:2500 individuals, DCM is familial in 20-35% of cases. Causal 
mutations have been identified in multiple cellular components for a considerable 
percentage of the cases [7].  
RCM results from stiff myocardial walls, making the heart unable to stretch and 
fill with blood properly [8]. ARVC, on the other hand, is characterized by myocardial 
fibrofatty replacement and affects about 1:1200 individuals, with more than half of cases 
having familial inheritance. ARVC manifests with ventricular tachyarrthythmias and 
sudden cardiac death. The arrthythmias originate from the right ventricle. Causal 
mutations are found in desmosomes, proteins that hold cells together [9 - 13].  
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Among the less well-studied, CPVT arises from mutations in calcium handling 
proteins such as Ryr2 and CASQ2 and can result in ventricular syncope during exercise 
[14].  CPVT is a rare condition with unknown prevalence. 
Left ventricular noncompaction originates from improper development of the 
myocardium and is characterized by a spongy left ventricular myocardium. Sarcomere 
gene mutations are causal for this disease [15, 16].  
Delineating genotype-phenotype relationships can be challenging and cannot 
currently be done based on the amino-acid sequence change alone. Using molecular 
genetics, defining associations between mutation and clinical status drives our 
investigations to identify disease-causing mutations [17 - 20]. To complicate our 
understanding further, different mutations in the same gene can have different clinical 
manifestations. For example, mutations in the myosin-heavy chain can cause either 
HCM or DCM as in the instances of Arg403Gln (HCM), Arg719Trp (HCM), Ser532Pro 
(DCM) and Phe764Leu (DCM) [2, 21]. In addition, the severity of the disease can vary 
depending on the exact mutation. The resulting phenotypes are thought to constitute a 
continuum, sharing symptoms and histologic hallmarks [22]. 
The relationship among the various cardiomyopathies with respect to the genes 
in which causal mutations are found is shown (Figure 1.1). Cardiomyopathies overlap 
with respect to the genes where causal mutations are found and in terms of the 
symptoms associated with each of them. For example, HCM and DCM share similar 
histopathologic findings such as fibrosis and myocyte death, although to different 
degrees. However, the genetic causes of DCM are currently described as more diverse 
than those of HCM and include mutations in cellular compartments such as the 
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cytoskeleton, nuclear envelope, calcium handling proteins, and elements involved in 
mechanotransduction [23]. 
In addition, mutations in a major sarcomere protein component, Titin, are now 
linked to DCM but not HCM. Next-generation sequencing has enabled the determination 
of causal mutations in Titin. In particular, a subgenome capture approach [24] was used 
to sequence Titin from DNA from multiple patients with HCM and DCM, in addition to 
normal controls. This was a considerable technological challenge, as Titin, is 33,000 
amino acids in length, spanning the entire sarcomere. The frequency of Titin mutations 
in patient DNA was 54/203 for DCM, 3/231 for HCM and 7/249 for normal controls [25] 
(Figure 1.2). This indicates that Titin mutations are causal for DCM and that Titin 
mutations may constitute a minor proportion of all HCM-causing mutations. Studies with 
much larger cohorts may eventually lead to identification of specific Titin mutations as 
factors for HCM. Alternatively, it may eventually be shown that alterations in Titin 
predispose the patient to develop only DCM. One observation from the overall data 
discussed thus far is that a particular mutation tends to exhibit a well-defined clinical 
course, despite the observed heterogeneity in its expression (with the caveat that when 
evaluating large cohorts, genotyping typically followed selection of patients). 
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Figure 1.2. Distribution of identified Titin mutations on the protein shown as it spans 
from the Z line to the M line of the sarcomere. Red or blue: Location of mutations in 
DCM patients. Black: Location of mutations in HCM patients and healthy controls. 
Reprinted from Herman et al., 2012 [25] with permission from the copyright holder 
(Massachusetts Medical Society). 
 
Hypertrophic Cardiomyopathy (HCM) and causal mutations 
HCM is an inherited cardiomyopathy, with 50% of cases having a determined 
genetic etiology. Sarcomere genes with HCM associated mutations are shown (Figure 
1.3). Mutations in 23 sarcomere and sarcomere-associated proteins are believed to 
cause HCM [22]. Interestingly, HCM appears to be a genetic disease caused by very 
defined mutations found mainly in two genes, MYH7 and MYBPC3, that account for 
~3/4 of identified genetic causes. Mutations in 8 genes depicted (Figure 1.4) are 
definitively linked with pathology in patient cohorts and they have autosomal dominant 
inheritance [26, 27]. 
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Figure 1.3. Depiction of the components of the sarcomere. A high magnification of the 
myosin and its components is shown on the upper right. Mutations in these sarcomere 
components are associated HCM as well as other primary cardiomyopathies. Reprinted 
from Frey et al., 2012 [22] with permission from the copyright holder. 
	   9	  
 
Figure 1.4. Distribution of HCM disease causing mutations in sarcomere genes. 
Mutations in these sarcomere genes are definitively linked with HCM. Reprinted from 
Marston, 2011 [26] with permission from the copyright holder. 
 
The roles of the proteins with mutations that definitively cause or possibly cause 
HCM and are used for diagnostic testing (Partners Laboratory for Molecular Medicine) 
are briefly described below2 [28, 29, 30]). These genes include energy production genes 
and genes responsible for organelle function, which cause HCM-like disease with 
profound cellular hallmarks. 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 Information retrieved from the National Center for Biotechnology Information (NCBI) or 
associated references. 
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ACTC1 cardiac actin one of the basic components of the 
sarcomere [31] 
ACTN2 actinin anchors actin filaments [32, 33] 
CSRP3 cysteine and glycine-rich 
protein 3 
mechanotrasduction at the Z-disk 
through a LIM domain [34] 
GLA galactosidase alpha lysosome protein with mutations 
causing Fabry disease and late onset 
cardiac hypertrophy 
LAMP2 lysosomal-associated 
membrane protein 2 
lysosome protein with roles in 
autophagy causing severe 
hypertrophy presenting like HCM in 
young males 
MYBPC3 cardiac myosin binding 
protein-C 
associates myosin and modulates 
cardiac contraction [35] 
MYH7 myosin-heavy chain beta constitutes the motor of the 
sarcomere by binding and moving 
along the actin filament. Possesses 
ATP hydrolysis and actin binding 
domains 
MYL2, 
MYL3 
myosin regulatory/essential 
light chains 
trigger contraction in response to 
calcium mediated phosphorylation. 
MYOZ2 myozenin 2 localizes at the Z disk. Mutations in 
this protein may interfere with Z disk 
function [36] 
NEXN nexilin actin binding protein 
PLN phospholamban regulates calcium levels by 
modulating the sarco/endoplasmic 
reticulum Calcium – ATPase channel 
(abbreciated as SERCA) 
PRKAG2 AMP-activated protein kinase 
subunit gamma-2 
energy sensitive molecule which 
when mutated causes a glycogen 
storage cardiac hypertrophy 
TNNC1 cardiac troponin C subunit of troponin that when bound 
to calcium relieves inhibition of 
contraction [37 – 39] 
TNNI3 troponin I type 3 inhibitory subunit of troponin blocking 
actin myosin interaction in the 
absence of calcium which accounts 
for the resting state 
TNNT2 cardiac troponin T part of the troponin complex, it 
stereochemically regulates 
tropomyosin inhibition of contraction 
[40, 41] 
TPM1 tropomyosin binds to actin and prevents myosin 
from binding (in the resting phase) 
locked position by troponins. This 
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inhibition is relieved in the presence 
of calcium [42] 
TTR transthyretin transports thyroxine, retinol (vitamin 
A), drugs etc. 
ANKRD1 ankyrin repeat domain 1 interacts with Titin and may act as a 
transcription factor [43] 
BAG3 BCL2-associated athanogene 
3 
associates with the sarcomere at the 
Z-disk location 
CAV3 caveolin 3 scaffolding protein 
LDB3 LIM domain binding 3 associates with the sarcomere at the 
Z-disk location, possibly providing 
stabilization 
MYH6 alpha cardiac myosin heavy 
chain 
the relative levels between alpha and 
beta myosin heavy chains fluctuate in 
development and disease [44] 
MYLK2 myosin light chain kinase 2 calcium dependent protein 
RYR2 ryanodine receptor 2 essential component of SERCA, 
important for regulation of calcium 
levels 
TCAP titin-cap binds to titin and is important for 
sarcomere assembly 
TTN titin large, essential cardiac protein 
provides passive force and active 
contractile force 
VCL vinculin interacts with actin and helps anchor 
actin to intercalated discs [45, 46] 
 
 
Cellular basis of HCM and non-sarcomere mutations causing HCM-like disease  
HCM is characterized by hypertrophy of the cardiac tissue (including at times the 
right ventricle), myocyte disarray, fibrosis, and enhanced contractility of the sarcomere 
due to mutations and symptoms such as shortness of breath, angina and palpitations. 
Also, HCM can be asymptomatic in many disease carriers even with overt disease. 
Patients are at risk for sudden cardiac death, heart failure, and stroke. Change in the 
contractile function occurs early in the disease [47]. 
HCM-causing mutations in several sarcomere proteins such as MyBP-C, 
tropomyosin, troponin T, troponin I and troponin C can alter calcium sensitivity and lead 
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to calcium accumulation during diastole. Increase of the affinity of troponin C with 
calcium can lead to a more gradual release of calcium that can persist during diastole. 
Increased affinity to calcium and higher than normal calcium levels during diastole can 
lead to an impairment of the cardiac muscle to properly relax [2].  
Dysregulation of energy homeostasis can occur due to changes in contractile 
properties which can then lead to hypertrophic signaling. This is because of the very 
high energetic demands of the sarcomere which when altered can consume more ATP. 
In physiological state, ATP consumption by the sarcomere accounts for 70% of total 
ATP in the myocyte. Depletion of energy can also lead to deficient function of ion-
pumps (such as the sarcoendoplasmic reticulum Ca2+ ATPase, SERCA) thus further 
contributing to calcium accumulation and predisposition to arrhythmias. Thus, increase 
in energy demand by a mutant sarcomere is thought to be a very prominent mechanism 
leading to pathology. Metabolic changes can also affect signaling leading to an overall 
change away from the physiological transcriptional state of the cell. In addition, 
mitochondrial disorders can lead to an HCM-like manifestation, further reinforcing the 
notion that such energy imbalances contribute to hypertrophic signaling [2, 22, 48 - 52]. 
 Mutations in the energy sensing subunit of AMPK, Prkag2, and the lysosomal 
proteins Lamp2 and Gla present with unique hallmarks and left ventricular hypertrophy 
that is distinct from HCM. Prkag2 mutations lead to glycogen accumulation in the 
myocytes with electrophysiological abnormalities, in addition to hypertrophy. Lamp2 
mutations cause massive cardiac hypertrophy in males, with autophagic vacuoles 
present at the histologic level. Gla mutations in the lysosomal galactosidase gene cause 
cardiac hypertrophy with other systemic effects. Mutant Lamp2 caused HCM typically 
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manifests in adolescence, with a rapid progression to heart failure, while HCM-like 
disease from mutated Gla has a late onset [53-56]. 
 
The molecular and cellular hallmarks of HCM 
The first identified genetic cause of HCM was an Arginine to Glutamine change 
at residue 403 (Arg403Gln) of the myosin heavy chain. This was accomplished by 
cloning, fine restriction enzyme site mapping and nucleotide sequence analysis of a 
family with familial HCM [57, 58] (Figure 1.5). This mutation is mapped to the globular 
head of the myosin near the ATPase site (Figure 1.6). It is noteworthy that a mutation in 
the adjacent residue 908 (just 15 nm further away from the motor domain) causes a 
milder form of HCM [59]. The functional location of the mutation as it relates to critical 
components of the myosin (Figure 1.7) may be directly associated with severity of the 
disease [60]. For example, the Arg403Gln mutation causes a severe, high-penetrant 
disease with 50% survival at 45 years [61].  
Figure 1.5. HCM co-segregating with Arg403Gln mutation with high penetrance. 
Squares: males. Circles: females. Filled: affected. Slash: deceased. 1/1: normal allele. 
½: Arg403Gln. Reprinted from Geisterfer-Lowrance et al., 1990 [57] with permission 
from the copyright holder. 
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Figure 1.6. Exon composition of the globular head and rod region of myosin. The 
Arg403Gln mutation occurs at exon 13 in the globular head and is shown with an arrow. 
Reprinted from Geisterfer-Lowrance et al., 1990 [57] with permission from the copyright 
holder. 
 
 
 
 
Figure 1.7. Depiction of myosin interacting with actin. Functional regions of the myosin 
head are detailed with A-D. A. Actin-binding region. B. Region of ATP hydrolysis. C. 
Myl3 binding region. D. Head-rod junction. Reprinted from Woo et al., 2003 [60] with 
permission from the copyright holder. 
 
	   15	  
Treatments for HCM aim to manage symptoms and prevent sudden cardiac 
death and surgical therapies aim to relieve left ventricular outflow obstruction. β-
adrenergic-receptor blockers, calcium-channel antagonists, or disopyramide are 
typically used. This treatment aims to lower contractility, decrease the heart rate and 
increase the duration of diastole. Diuretics can be used to relieve congestion. Surgical 
septal myectomy or alcohol ablation are the gold standard for symptom relief for 
individuals not responding to drug therapy when the left outflow tract is obstructed 
(Hypertrophic obstructive cardiomyopathy); this operation is associated with a high 
success rate and long term symptom relief. Implantable defibrillators are effective at 
reducing the risk of sudden cardiac death in those with severe arrhythmias [62-67]. 
Further work to improve the efficacy of available treatments is warranted. 
 Recapitulating HCM in animal models was an important achievement toward 
understanding the molecular and process determinants of the disease. The first mouse 
model of HCM was generated by introducing the Arg403Gln mutation in the respective 
mouse myosin heavy chain. Left atrial enlargement was observed in these mice (at 15 
weeks), followed by cardiac hypertrophy and all classic histopathology landmarks, such 
as hypertrophied myocytes with large hyperchromatic nuclei, myocyte disarray, and 
fibrosis. Histology of these mice is shown (Figure 1.8). Also mirroring human symptoms, 
these mice were less tolerant to exercise than wild-type mice. In addition, females 
showed a slower progression to disease compared to males from the same inbred 
genetic background, providing evidence for genetically derived disease modifying 
processes, meaning that expressed differences between males and females can only 
account for the differences in disease expression. Such processes were postulated to 
	   16	  
potentially account for the observations that some human carriers died before reaching 
adulthood, while others had normal lifespans [68]. 
 
Figure 1.8. Myocyte disarray and fibrosis in Arg403Gln mice recapitulating human HCM 
histology. Staining: top panels, H&E; lower panels, masson’s trichrome (staining fibrotic 
regions blue). (Left) Mice carriers of the sarcomere mutation. (Right) Wild-type controls. 
Reprinted from Geisterfer-Lowrance et al., 1996 [68] with permission from AAAS. 
 
Fibrosis, which is an important histological landmark in HCM, can be seen in 
patients histologically or with magnetic resonance imaging (MRI). In human carriers 
without or with overt hypertrophy, fibrosis is detected using gadolinium as a contrast 
agent. In addition to MRI showing thickening of the intraventricular septum (IVS), foci of 
fibrosis are observed (Figure 1.9). Propeptide of type I procollagen (PICP) precedes 
overt hypertrophy or MRI findings [69]. 
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Figure 1.9. Magnetic resonance imaging can detect hallmarks of HCM in carriers of 
disease causing mutations. (Left panels) A carrier without overt hypertrophy. (Right 
panels) A carrier with overt hypertrophy. Reprinted from Ho et al., 2010 [69] with 
permission from the copyright holder (Massachusetts Medical Society). 
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Transcriptome analysis identifies pro-fibrotic molecules essential to the 
development of HCM 
 
Early analysis of the transcriptome with high-throughput sequencing was 
performed in mice carriers of the Arg403Gln mutation. This new technology enabled a 
digital analysis of genes that changed expression in HCM (Figure 1.10). Of particular 
interest, this analysis identified specific profibrotic markers that were elevated in hearts 
of pre-hypertrophic mice, pointing to specific pathways altered in HCM such as the 
Transforming growth factor beta 1 (TGF-β1) pathway [70]. 
 
Figure 1.10. A high throughput sequencing approach utilizing parallel sequencing of 
cDNA tags is shown. A. Molecular biology steps to prepare and amplify cDNA tags 
amplified on polony beads. B-E. Sequencing of tags on glass by processing of 
fluorophore clusters. Application of this method identified the early fibrotic processes in 
HCM. Reprinted from Kim et al., 2007 [70] with permission from the copyright holder. 
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Experimental follow-up verified active proliferation of non-myocyte cells in HCM 
and allowed for testing of these pro-fibrotic factors. Interestingly, periostin, TGF-β1, and 
associated processes inhibited by losartan (an angiotensin inhibitor which is involved in 
TGF-β1 signaling) are essential for the development of HCM (Figure 1.11). This showed 
that targeting early prehypertrophic processes in non-myocytes identified by 
transcriptional analysis resulted in abrogation of the hypertrophic response from the 
sarcomere mutation [71]. 
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Processes impacted by a sarcomere mutation 
Models incorporating these findings provide a depiction of the critical pathways 
responsible for disease development arising from the initial mutation. Biomechanical 
stress sensing, followed by calcium sensitization, disturbed energy homeostasis, and 
downstream pathologic responses are shown as potential targets for drugs to 
ameliorate or prevent the onset of HCM (Figure 1.12). Calcium desensitizers (such as 
blebbistatin) or calcium channel inhibitors (such as L-type calcium channel antagonists) 
can target early disease processes in the myocytes (calcium blockers are already 
prescribed for alleviating the symptoms of HCM). Drugs that augment energy production 
such as perhexiline, which shifts energy production from fatty acids to glucose with 
higher ATP yield, utilize the notion that energy depletion is an important mediator. 
Metalocorticoid antagonists, statins, angiotensin II antagonists, and TGF-β1 inhibitors 
may prevent pathologic remodeling [22].  
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Figure 1.12. Depiction of processes and pathways responsible for HCM that can be 
potentially pharmacologically targeted. Reprinted from Frey et al., 2012 [22] with 
permission from the copyright holder. 
 
A similar model depicting relationships between myocytes and fibroblasts is 
shown (Figure 1.13). Changes in ATP utilization, sliding velocity, force generation and 
calcium sensitivity are shown occurring at the myocyte level. Potential early and later 
interventions are shown. Stressed myocytes are shown to transduce signals to 
quiescent non-myocytes, causing the fibrotic response. This signal can be chemical (a 
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secreted molecule) or physical (e.g. force transmission). TGF-β1 which is a proven 
essential mediator of the pathology is shown as a potential pharmacological target. 
Non-myocytes are shown engulfing myocytes, possibly contributing to myocyte death. 
Additional signaling or intercellular communication may add to overall myocyte stress 
[72]. 
 
 
Figure 1.13. Myocyte and non-myocyte interactions are shown as crucial parts in the 
development of the pathology in HCM with opportunities for pharmacology intervention. 
Reprinted from Teekakirikul et al., 2012 [72] in accordance with the copyright. 
 
 Although myocytes account for the largest fraction of the heart by volume, non-
myocytes may exceed myocytes in number. Non-myocytes present in the heart include 
fibroblasts, smooth muscle, endothelial cells and blood cells. Of particular importance is 
the cardiac fibroblast which has significant roles in cardiac physiology and disease. The 
cardiac fibroblast and its diverse functional roles in the heart and disease are shown 
(Figure 1.14). Physiologically, fibroblasts secrete and regulate collagen, which provides 
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tensile strength and is essential for cardiac function. Fibroblasts are also recruited in 
areas of myocardial scaring providing structural integrity at those locations. Such broad 
roles can afford a high complexity in its function. Fibroblasts have roles in regulating 
physiological myocardial function and are essential for cardiac remodeling in HCM, left 
ventricular hypertrophy, myocardial infarction and heart failure. By secreting growth 
factors, they can facilitate wound healing. Such response processes are thought to 
contribute in maladaptive remodeling [73, 74].  
In addition, a myofibroblast phenotype arising possibly because the fibroblast cell 
expresses contractile proteins exhibits potentially crucial effects. This cell has migratory 
and proliferative properties. Myofibroblasts are responsive to diverse, systemic signals 
including cytokines, vasoactive peptides, and hormones. Myofibroblasts can also 
secrete metalloproteases, which degrade the collagen, thus they directly regulate 
collagen turnover and matrix consistency [73]. 
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Figure 1.14. Depiction of the diverse functional roles of cardiac fibroblasts indicating a 
wealth of possible roles in normal physiology that can be found dysregulated in HCM. 
Reprinted from Porter and Turner, 2009 [73] with permission from the copyright holder. 
 
The role of the myocyte in disease is of central importance in HCM as the 
sarcomere mutation is expressed in the myocyte. Thus, the myocyte is central to the 
first steps of HCM development. Enhanced biophysical/contractile properties of the 
mutant sarcomere were identified in HCM. This is measured as a sliding velocity 
between myosin and actin which appears to be quantal in nature, i.e. the myosin moves 
on the actin in discrete steps measured to be ~7nm, which may represent the distance 
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between the myosin binding sites on the actin polymer. Increase of sliding velocity can 
be a direct effect of a reduction of the time that myosin remains on the actin (in the 
context of a myosin mutation), resulting in enhanced contractile properties of the 
sarcomere (Figure 1.15). A mutation potentially de-stabilizing actin binding to myosin 
could have such an effect. In both human and mouse HCM models, increased ATPase 
activity, force generation, and increased sliding velocities were observed [59, 75, 76].   
In addition, stressed myocytes induce the expression of the transcription factor 
myocyte enahancement factor 2 (Mef2) possibly due to increased phosphorylated 
histone deacetylases and involvement from Ca2+/calmodulin-dependent protein kinase 
II, implicating Mef2 signaling in response processes in myocytes [77]. 
 
Figure 1.15. Biophysical differences between wild-type (+/+) and mutant (403/403) 
sarcomeres (representative data). Arrows: Actomyosin interaction resulting in a unitary 
displacement measured by an optical trap. Reprinted from Tyska et al., 2000 [76] with 
permission from the copyright holder. 
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Dissertation focus 
The observation that HCM can be markedly heterogenenous even when it is 
caused by the same mutation points to the role of genetic, epigenetic and environmental 
factors in disease pathogenesis (Figure 1.16). Understanding these factors and 
processes can be of immense benefit in treating the disease. Compensatory factors can 
provide relief and provide new avenues for treatment. On the other hand, 
decompensatory environmental factors can be avoided [2]. 
The evolution of relevant technologies and methods allows wider and greater-
depth assessment of disease processes. This dissertation undertook the task of 
developing methods based on next-generation sequencing to analyze the transcriptome 
of cells [78]. These methods have been applied in various cardiovascular or other 
biological contexts and in conjunction with follow-up analyses and experiments 
contributed to new insights [25, 79-82]. An early focus on genes that change start-site 
usage enabled usage of transcriptome data beyond the most commonly used gene 
expression analyses. As cells may utilize different start-sites to execute advanced 
transcriptional programs, we hypothesized that genes that change their 5' ends may 
serve important functions. 
 
The remainder of this dissertation is organized as follows: 
- Chapter 2 discusses the development of the Deep Sequencing Analysis of Gene 
Expression method and analytical tools. 
- Chapter 3 discusses the development of normalizing cDNA libraries in order to 
facilitate increased sequencing of low expressing transcripts. 
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- Chapter 4 discusses the development of an approach to sequence miRNA, construct 
and compare miRNA profiles. 
- Chapter 5 discusses the development of a complete framework involving library 
construction and analysis to assess start-site changes between samples. Applied in 
HCM, this method allowed the detection of Four-and-a-half LIM domains protein 1 as 
being critically regulated in HCM in stressed myocytes and providing for a 
compensatory function. 
- Chapter 6 discusses conclusions and future directions. 
 
Figure 1.16. Genetic, epigenetic and environmental factors can affect the progression 
from causal mutation to HCM. Reprinted from Watkins et al., 2011 [2] with permission 
from the copyright holder (Massachusetts Medical Society). 
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Chapter 2. Quantification of Gene Transcripts with Deep Sequencing Analysis of 
Gene Expression (DSAGE) Using 1 to 2 µg Total RNA:  
Published in Current Protocols of Molecular Biology (Curr Protoc Mol Biol. 2011 
Jan;Chapter 25:Unit25B.9). Reproduced with permission of Current Protocols and John 
Wiley & Sons, Inc. Copyright © 2011 by John Wiley & Sons, Inc. 
 
Danos C. Christodoulou, Joshua M. Gorham, Masataka Kawana, Steven R. DePalma, 
Daniel S. Herman, Hiroko Wakimoto 
 
Introduction  
Deep sequencing analysis of gene expression (DSAGE) measures global gene 
transcript levels from only 1 to 2 µg total RNA by massively parallel sequencing of cDNA 
tags. First, 21-bp cDNA tags are generated by NlaIII digestion of the cDNA, followed by 
MmeI cleavage. The cDNA tags are then queried by massively parallel sequencing and 
aligned to a reference genome and transcriptome (or any available gene sequences) 
using Bowtie, an ultra-high-throughput short-read aligner, and Tophat, a fast splice-
junction mapper. Analysis of 10 to 20 million tags, acquired using one lane of an 
Illumina Genome Analyzer II, provides sufficient depth to quantify gene expression and 
detect rare transcripts. Typically, we observe the expression of 15,000 genes in the 
cardiac left ventricle, including gene transcripts expressed at levels as low as one copy 
per cell. These expression profiles are highly reproducible (r > 0.99 between technical 
replicates), enabling sensitive detection of differences between experimental conditions 
as well as assessment of the relative transcript abundance of different genes. The 
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significance of these differences is assessed, while accounting for multiple 
comparisons, using a false discovery rate approach. Thus, DSAGE can be used to 
quantify gene expression profiles and assess differential expression with high 
sensitivity, and requires small amounts of biological material. 
 
Basic Protocol 1 describes the construction of 21-bp cDNA tag libraries appropriate for 
massively parallel sequencing and the analysis of the resulting sequence data. The 
adapter oligonucleotides used are optimized for sequencing with current Illumina 
massively parallel sequencers. A step-by-step implementation of the analysis protocol is 
described (see Basic Protocol 2), which is compiled into three steps (Alternate 
Protocol). 
  
Basic Protocol 1: DSAGE Library Construction 
Construction of the DSAGE library begins with extraction of 1 to 2 µg high-quality RNA. 
If it is desirable to minimize biological noise, RNA can be pooled from three to five 
sample replicates. RNA can be extracted using the RNAeasy kit (Qiagen) or a standard 
protocol using Trizol (Invitrogen). RNA quality can be assessed by running an aliquot on 
a Bioanalyzer (Agilent; Schroeder et al., 2006) or an agarose gel. Good-quality RNA 
has a ~2:1 ratio of 28S to 18S RNA. 
 
An overview of the subsequent steps is presented in Figure 2.1. Poly(A) RNA is 
captured on Dynal(dT) beads. Reverse transcription, second strand synthesis, NlaIII 
digestion, and adapter 1 ligation are performed with the poly(A) tail of the original RNA 
attached to the beads. NlaIII cleaves cDNA at defined sites, and subsequent washes of 
the beads remove all but the 3’ fragment of the cDNA. Adapter 1 is then ligated to the 
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overhang resulting from NlaIII digestion, creating an MmeI site at the overlap of the 
NlaIII site (cDNA) and the adapter sequence. MmeI cuts 18/20-bp downstream of its 
recognition site, releasing a 21-bp tag with a 2-bp overhang attached to adapter 1. 
Adapter 2 is then ligated to the released fragment, and the resulting molecules are 
amplified by PCR. To avoid amplification bias, a mock reaction is monitored by real-time 
PCR, and the subsequent library amplification is performed within the log phase of the 
reaction. The PCR product is then purified, quantified, and submitted for sequencing at 
a concentration of 10 nM library molecules. The sequencing is typically performed by a 
core facility and is described in detail in Bentley et al. (2008). 
 
 
Figure 2.1 cDNA library construction for DSAGE. mRNA is selected from total RNA using oligo(dT) 
ferromagnetic beads, and double-stranded cDNA is synthesized while the mRNA is bound to the beads. 
cDNA is then cleaved with anchoring enzyme NlaIII, leaving a 4-bp 3’overhang (CATG), which is ligated 
to a forward adapter containing an MmeI restriction site. MmeI cuts 20 bp downstream of the non-
palindromic recognition site, generating a 21-bp unique tag sequence for each mRNA transcript. Finally, 
the reverse adapter containing a 2-bp 3’ degenerate overhang is ligated. 
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The adapter oligonucleotides are designed to work with standard Illumina Genome 
Analyzer flow cells and amplification primers. This protocol describes the use of a 
sequencing primer that overlaps the common NlaIII site and reduces the number of 
cycles needed for sequencing to 17. 
 
 Materials 
• Dynabeads mRNA DIRECT Kit (Invitrogen, cat. #610-12), including oligo(dT) 
beads, lysis buffer, buffer A, and buffer B 
• High-quality RNA, optionally from three to five sample replicates, extracted using 
RNAeasy kit (Qiagen, cat. #74104) or standard protocol using Trizol (Invitrogen, 
cat. #15596-018) 
• SuperScript II reverse transcriptase (Invitrogen, cat. #18064-022), including First 
Strand Buffer, DTT, and 10 mM dNTPs 
• Second-Strand Buffer (Invitrogen, cat. #10812-014) 
• E. coli DNA polymerase I (Invitrogen, cat. #18010025) 
• E. coli DNA ligase (Invitrogen, cat. #18052019) 
• E. coli RNase H (Invitrogen, cat. #18021071) 
• Buffers C, D, and E (see recipes) 
• LoTE buffer (see recipe) 
• 100× BSA (New England Biolabs, cat. #B9001S) 
• NEBuffer 4 (New England Biolabs, cat. #B7004S) 
• 0.5 M EDTA, pH 8.0 (APPENDIX 2) 
• NlaIII (New England Biolabs, cat. #R0125L) 
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• Adapters 1 and 2 (see recipe) 
• T4 DNA ligase, high concentration, with ligase buffer (Invitrogen, cat. #15224-
041) 
• MmeI (New England Biolabs, cat. #R0637L) with S-adenosylmethionine (SAM) 
• Phenol/chloroform (Ambion, cat. #AM9732), adjusted to pH 7.5-8 
• GlycoBlue (Ambion, cat. #AM9515) 
• 7.5 M ammonium acetate (APPENDIX 2) 
• 100% ethanol 
• 10× BlueJuice gel loading buffer (Invitrogen, cat. #10816-015) 
• Novex 20% TBE gels (Invitrogen, cat. #EC6315BOX) 
• Low-molecular-weight DNA ladder (New England Biolabs, cat. #N3233S) 
• SYBR Green I (Invitrogen, cat. #S7563) 
• Glycogen (Roche, cat. #10901393001) 
• MGB buffer (see recipe) 
• Dimethyl sulfoxide (DMSO) 
• 10 mM dNTP mix 
• 100 µM GexPCR primers A and B (Integrated DNA Technologies): 
o 5’-CAAGCAGAAGACGGCATACGA 
o 5’-AATGATACGGCGACCACCGACAGGTTCAGAGTTCTACAGTCCGA 
• Platinum Taq DNA polymerase (Invitrogen, cat. #10966034) 
• Quant-iT dsDNA HS Assay Kit (Invitrogen, cat. #Q32851) 
• 0.5- and 1.5-ml non-stick RNase-free microcentrifuge tubes (Ambion, cat. 
#12350 and 12450) 
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• DynaMag-2 magnet (Invitrogen, cat. #123-21D) 
• 16°C water bath 
• 50° and 60°C heating blocks 
• UV light source 
• 18-G needle 
• Spin-X centrifuge tube filters (Corning, cat. #8161) 
• Thermocycler 
• Qubit fluorometer (Invitrogen, cat. #Q32857) 
• Additional reagents and equipment for polyacrylamide (UNIT 2.7) and agarose 
(UNIT 2.5A) gel electrophoresis 
 
 Stage I: Capture RNA, reverse transcribe, and synthesize cDNA 
 1. Transfer 100 µl oligo(dT) Dynabeads to a 1.5-ml non-stick microcentrifuge tube. 
Capture the beads by placing the tube on a DynaMag-2 magnet, pipet out the 
buffer, and quickly resuspend the beads in 500 µl lysis buffer (supplied in the 
Dynabeads kit). 
Non-stick tubes are used throughout the experiment. 
 2. Add 1-2 µg RNA and incubate for 10 min with gentle agitation. 
 3. Capture the beads with the bound RNA on the magnet, remove the supernatant, 
and wash as follows: 
• Twice with 500 µl buffer A (Dynabeads kit) 
• Once with 500 µl buffer B (Dynabeads kit) 
• Twice with 200 µl 1× First Strand Buffer (SuperScript II kit) 
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 4. Prepare the following mix: 
• 18 µl 5× First Strand Buffer 
• 9 µl 0.1 M DTT 
• 4.5 µl 10 mM dNTPs 
• 55.5 µl ddH2O 
Vortex, briefly microcentrifuge to collect the solution at the bottom of the tube, and 
keep on ice. 
 5. Resuspend washed beads in the mix and place tubes at 37°C for 2 min. 
 6. Add 3 µl Superscript II reverse transcriptase, vortex gently, and incubate for 1 hr at 
37°C. Mix beads every 20 min by gentle vortexing. 
 7. Place the tubes on ice and add the following components in the order shown:  
• 465 µl prechilled ddH2O 
• 150 µl of 5× Second Strand Buffer 
• 15 µl 10 mM dNTPs 
• 5 µl E. coli DNA ligase 
• 20 µl E. coli DNA polymerase I 
• 5 µl E. coli RNase H 
Incubate 2 hr in a 16°C water bath. Vortex gently every 20 min. 
 8. During the 2-hr incubation, preheat buffer C to 75°C and prepare the NlaIII mix for 
each sample: 
• 172 µl LoTE 
• 2 µl 100× BSA 
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• 20 µl 10× NEBuffer 4 
• Keep the above mix on ice. 
 9. Following second strand synthesis, add 45 µl of 0.5 M EDTA to stop the reaction. 
Capture the beads on the magnet and remove the reaction liquid. 
 10. Resuspend the beads in 450 µl preheated buffer C and incubate at 75°C for 12 min 
with intermittent gentle vortexing. 
 11. Capture the beads using the magnet and wash once more with preheated buffer C. 
Under these conditions, the beads tend to clump on the tube. If this occurs, scrape 
the clumped beads from the tube using a pipet tip and proceed quickly, since SDS 
tends to precipitate. 
 12. Capture beads, remove solution, and resuspend beads in 500 µl buffer D. 
 13. Transfer resuspended beads to a new tube, wash twice with 200 µl buffer D, then 
twice with 200 µl buffer E. 
 Stage II: Cleave cDNA with NlaIII and ligate adapter 1 
 14. Add 6 µl NlaIII to the prepared NlaIII mix from step 8. Resuspend beads in the mix 
and incubate for 1 hr at 37°C. 
 15. Wash beads two times with 450 µl buffer C (preheated to 37°C). Wash quickly 
since SDS tends to precipitate. 
 16. Wash twice with 200 µl buffer D and transfer the bead slurry to a new tube. 
At this stage the beads can be kept rotating overnight at 4°C, if desired. 
 17. Wash once more with buffer D, twice with 200 µl of 1× ligase buffer, and once with 
50 µl of 1× ligase buffer. 
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At this stage, keep the beads in ligase buffer on ice if multiple samples are being 
handled. 
 18. Capture beads using the magnet, remove the solution, and resuspend in the 
following mix:  
• 11.5 µl LoTE 
• 4 µl 5× DNA ligase buffer 
• 2 µl adapter 1 (final 50 µM) 
• Incubate 2 min in a 50°C heating block, then 10 min at room temperature. 
Place the tubes on ice. 
 19. Add 2.5 µl T4 DNA ligase (high conc.) and incubate in a 16°C water bath for 2 hr. 
Mix beads every 20 min by gentle vortexing. 
 Stage III: Digest with MmeI, ligate adapter 2, and gel purify 
 20. During the ligase incubation (step 19), dilute 32 mM SAM (provided with MmeI) to 
make the following 10× SAM solution (prepare fresh): 
• 3 µl 32 mM SAM 
• 24 µl 10× NEBuffer 4 
• 213 µl ddH2O 
 21. Prepare the MmeI mix just before use: 
• 20 µl 10× NEBuffer 4 
• 20 µl 10× SAM solution 
• 150 µl ddH2O 
 22. After ligation, wash the beads three times with 200 µl buffer D, resuspend in 200 µl 
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buffer E, and transfer the bead slurry to a new tube. Wash once more with buffer E. 
 23. Preheat the MmeI mix for 2 min at 37°C. Capture the beads on the magnet and 
discard the buffer. 
 24. Quickly add 10 µl MmeI enzyme to the preheated MmeI mix and use to resuspend 
the beads (160 µl/sample). Vortex gently and incubate for 2 hr at 37°C. Mix beads 
every 20 min by gentle vortexing. 
 25. Microcentrifuge for 2 min at 14,000 rpm, room temperature. Transfer the 
supernatant to a new tube. 
 26. To collect any residual material, add 100 µl LoTE to the beads, mix, and 
recentrifuge. Place on the magnet and transfer the 100 µl supernatant to the 
previous tube (total 300 µl). Discard the beads. 
 27. To assess contamination, transfer a 40-µl aliquot to a new tube, label as the “ligase 
minus control”, and adjust the volume of the remaining sample back to 300 µl with 
LoTE. Process the sample and control identically through step 30. 
 28. Add 300 µl phenol/chloroform, vortex, and microcentrifuge 2 min at 14,000 rpm. 
Transfer aqueous phase to a new tube. 
 29. To precipitate, add 2 µl Glycoblue and 133 µl of 7.5 M ammonium acetate and mix. 
Add 1 ml of 100% ethanol, vortex immediately, and precipitate at –80°C for at least 
30 min. 
At this stage the sample can be kept overnight at –80°C. 
 30. Microcentrifuge 30 min at 14,000 rpm, 4°C. Wash two times with 500 µl cold 70% 
ethanol. Remove the second wash, allow the pellet to air dry, and resuspend in 2 µl 
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LoTE. 
 31. Add the following and mix by pipetting:  
• 2 µl 5× ligase buffer 
• 2 µl adapter 2 (final 50 µM) 
• 2 µl ddH2O 
• 2 µl T4 DNA ligase (high conc.) 
Use water instead of ligase in the “ligase minus control”. Incubate both the sample 
and control overnight at 16°C in a thermocycler. Set control aside at –20°C until 
step 41. 
 32. Add 2 µl LoTE and 3 µl of 5× BlueJuice gel loading buffer to the sample ligation. 
Load sample in one lane of a 20% TBE gel, load low-molecular-weight DNA ladder 
in a separate lane, and run until the blue dye front reaches the bottom of the gel (~2 
hr). 
 33. Stain with SYBR green for 15 min at room temperature. Visualize with a UV light 
and excise the gel band corresponding to 66 bp (Fig. 2.2). 
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Figure 2.2 Library excision from a 
polyacrylamide gel. The 66-bp pre-PCR library 
(A) and the final amplified 88-bp library (B) are 
shown. 
 
 34. Place the excised band into a 0.5-ml tube with a hole punctured in the bottom using 
an 18-G needle, and place the 0.5-ml tube in a 1.5-ml tube. Crush the extracted gel 
by centrifuging 6 min at 14,000 rpm, collecting the crushed gel in the 1.5-ml tube. 
 35. Add 250 µl LoTE and 50 µl of 7.5 M ammonium acetate. Vortex and heat in a 60°C 
heating block for 15 min. 
 36. Pre-wet a SpinX column with 5 µl LoTE and add the sample. Centrifuge 5 min at 
14,000 rpm, room temperature. 
 37. Add 3 µl glycogen and 133 µl of 7.5 M ammonium acetate, mix, and precipitate with 
1 ml 100% ethanol at –80°C. 
The sample can be stored overnight at –80°C. 
 38. Centrifuge 15 min at 14,000 rpm, 4°C. Wash two times with 500 µl of 70% ethanol, 
air dry pellet, and resuspend in 14 µl LoTE. 
The library can be stored up to several days at –20°C. 
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 Stage IV: Amplify library 
 39. To determine the optimal number of cycles, perform a mock reaction for qPCR 
including SYBR Green. For each sample assemble: 
• 5 µl 10× MGB PCR buffer 
• 2.5 µl DMSO 
• 3 µl 10 mM dNTP mix 
• 1 µl 100 µM GexPCR primer A 
• 1 µl 100 µM GexPCR primer B 
• 35 µl ddH2O 
• 1 µl 5 U/µl Platinum Taq 
• 0.5 µl 10× SYBR Green 
• 1 µl library 
Amplification conditions:  
1 cycle: 94°C for 1 min 
24 cycles: 94°C for 30 sec 
 57°C for 30 sec 
 72°C for 1 min 
1 cycle: 72°C for 5 min 
 
 
 40. Determine the optimal cycle number for final amplification. An optimal cycle can be 
chosen at the mid-upper part of the linear phase of the curve. Run on a 4% agarose 
gel to confirm that the size of the amplified product is 88 bp. 
 41. Prepare a new reaction mix as in step 39, but omit SYBR Green and increase water 
to 35.5 µl. Perform final library amplification using the predetermined optimal 
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number of cycles. At the same time, amplify the ligase minus control (step 31) for 
40 cycles using the same conditions. 
 42. Run the control on a 4% agarose gel to assess contamination. If an 88-bp band is 
present, follow steps in the Table 2.1. 
 43. Add 10 µl of 6× BlueJuice gel loading buffer to the library and load in three lanes of 
a 20% TBE gel. Load low-molecular-weight ladder in a separate lane and 
electrophorese. 
 44. Repeat steps 32 to 38 to extract the 88-bp band (Fig. 2.2B). 
The added 22-bp sequence is used during sequencing. 
 45. Use a 1-µl aliquot to assess concentration on a Qubit fluorometer, and submit ~0.6 
ng/µl for sequencing. 
Only 17 cycles are needed when the following sequencing primer is used: 
5’-CCGACAGGTTCAGAGTTCTACAGTCCGACATG 
  
Basic Protocol 2: Generation and Comparison of Gene Expression Profiles 
For the purpose of this analysis, it is assumed that the DNA sequences are available in 
FASTQ format. To recapitulate the full-length cDNA tag sequence, the NlaIII site is 
appended to the beginning of DNA sequences. The resulting 21-bp tag is aligned first to 
the genome and then the transcriptome using Bowtie and Tophat (Langmead et al., 
2009; Trapnell et al., 2009). Here, Tophat is provided with a list of known splice 
junctions to enable alignment to the transcriptome. These junctions can be generated 
from a UCSC annotation table (see Support Protocol). The number of sequence tags 
aligned to each gene transcript is then tallied to generate gene expression profiles. 
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Sample profiles are normalized to one million gene-aligned tags. Between each pair of 
samples, the fold-difference and significance of the difference are calculated (Audic and 
Claverie, 1997). An overview of the analysis pipeline is shown in Figure 2.3. 
  
 
Figure 2.3 Data analysis pipeline. Sequenced tags in the FASTQ file are aligned to the genome and 
transcriptome. Gene expression profiles are generated by tallying the aligned tags for each gene. The 
resulting expression profiles can be compared to assess fold change and significance in gene 
expression.  
 
 
Materials 
• Software pre-requisites (if using versions other than indicated, test for 
compatibility): 
o Bowtie 0.12.6 
o Samtools 0.1.11 
o Tophat 1.1.4 
o BioPerl-1.6.1 
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o Bio-SamTools 1.24 
o Perl v5.10.0 
o BioPerl module for SAGE comparison 
o Integrative Genomics Viewer 
• Analysis software package includes: 
o Analysis programs written in Perl 
o Reference files 
• Software package requires a Unix-based computer; a computing cluster is 
strongly recommended (run time ~1-2 hr using a 2.4-GHz computing node) 
 
 1. Download and install the following programs:  
1. Bowtie: http://bowtie-bio.sourceforge.net/index.shtml. Follow installation 
instructions and add the program to the PATH. 
2. Samtools: http://samtools.sourceforge.net/ (Li et al., 2009). Add the installed 
program to the PATH. 
3. Tophat: http://tophat.cbcb.umd.edu/. Follow the directions for working with 
Samtools. Add the installed program to the PATH. 
4. BioPerl: http://www.bioperl.org/. 
5. Bio-Samtools module: http://search.cpan.org/~lds/Bio-SamTools/. Add the 
module's path to the PERL library environment variable. (Use PERL5LIB for 
Perl 5 if the module cannot be installed in the standard BioPerl location.) 
6. Perl: http://www.perl.org/. 
7. BioPerl module for SAGE comparison by algorithm of Audic and Claverie, 
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http://search.cpan.org/~scottzed/Bio-SAGE-Comparison-1.00/. Add the 
module's path to the PERL library environment variable (as above). 
8. Integrative Genomics Viewer (IGV): http://www.broadinstitute.org/igv. 
 2. Download the analysis package: http://seidman.med.harvard.edu/gs/DSAGE/. 
Unpack the files in a new directory (substitute “/dir/” below with the directory 
location). 
tar xvfz <downloaded package> 
Add the /dir/DSAGE/bin to the PATH. 
Add the following as environment variables to ~/.bash profile (assumes the bash 
shell is used). 
export DSAGE_TABLES=/dir/DSAGE/tables 
 3. Append the NlaIII sequence. Run: 
appendNlaIII.pl <Fastq file> 
The output will be <Fastq file>.NlaIII. 
 4. Align the tags from the appended FASTQ file with Tophat allowing 0 mismatches 
and by supplying known junctions: 
Run Tophat in the same folder (best if the job is submitted by bsub if a computer 
cluster is used). 
tophat –solexa1.3-quals -o <Sample name_folder> --segment-mismatches 0 -j 
$DSAGE_TABLES/<SPECIES>.juncs <REFGENOME> <Fastq file>.NlaIII 
For <REF GENOME>, follow the instructions on the bowtie website to generate or 
download the genome. 
In steps 4-7, for <SPECIES>, use mm9 for mouse, hg19 for human, or galGal3 for 
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chicken. For <Sample name>, use a one-word description of the sample. 
The output is a binary sequence alignment/map file (.bam). 
 5. Create an index file. Inside the Sample folder run:  
• samtools index accepted_hits.bam 
 6. Make a coverage file using the ‘wiggles’ program from the Tophat bin folder. Then 
normalize, name, and compress the coverage file:  
• samtools view accepted_hits.bam > accepted_hits.sam 
• wiggles accepted_hits.sam coverage.wig 
• normwig.pl coverage.wig <Sample name> 
The output file is <Sample_name>_norm.wig.gz, and can be uploaded to the UCSC 
browser as a custom track. The BAM file can also be uploaded. 
For more information on how to generate custom tracks, see 
http://genome.ucsc.edu/goldenPath/help/hgTracksHelp.html#CustomTracks. 
For genes that are highly expressed, IGV is recommended. 
At this stage, the aligned tags or the tag depth can be visualized on the UCSC 
Genome Browser (UNIT 19.9) as illustrated in Figure 2.4. 
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Figure 2.4 Tags aligned to the Nkx2-5 locus 
from mouse left ventricle. Nkx2-5 has three 
NlaIII sites found in the first exon (denoted by 
an asterisk). The majority of the sequence 
tags were aligned to the most 3’ NlaIII site, 
indicating that digestion with NlaIII was nearly 
complete. 
 
 7. Count sequence tags aligned to each gene transcript to construct the expression 
profile.  
• countreads.pl accepted_hits.bam $DSAGE_TABLES/<SPECIES>.ann 
The output file, which is the expression profile of the sample, is “genes.counts”. 
 8. Assemble, normalize, and compare expression profiles. Also append gene 
annotation. Read counts are normalized to one million reads. 
If running this command in the directory above the Tophat folders and if comparing 
two samples, run: 
expression_analyze.pl $DSAGE_TABLES/<SPECIES>.ann <Sample1> <Sample2> 
where the sample name is the name given previously to the Tophat folder. 
For multiple samples, run: 
expression_analyze.pl $DSAGE_TABLES/<SPECIES>.ann <Sample1> <Sample2> 
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<Sample 3> [ ] <Sample N> 
In case the comparison involves samples run at different parent directories, the 
location of the Tophat folder can be included for any or all samples following the 
sample name. The location should be preceded with “dir:” (no spaces): 
expression analyze.pl $DSAGE_TABLES/<SPECIES>.ann <Sample 1> dir:</dir1> 
<Sample 2> dir:</dir2> [ ] <Sample N> dir:</dirN> 
The output file is called <Sample1 Sample2.. SampleN>.expr. 
  
Alternate Protocol: Automated Generation of Expression Profiles for Multiple 
Samples 
While a step-by-step approach is needed to test individual components of the process 
(e.g., when running the analysis pipeline for the first time), automation is essential for 
the analysis of multiple samples (e.g., to troubleshoot or make modifications), as it can 
save time and minimize errors. This protocol offers tools to automate the generation of 
expression profiles for multiple samples into a single step. 
 
 1. Create a tab-delimited text input file, e.g., ‘Samples.txt’ 
• First column: FASTQ file (full path if not running in the same directory) 
• Second column: Sample name 
• Third column: Species (e.g., mm9, hg19, galGal3). 
The sample name must match the Bowtie index genome. 
 2. To execute steps 3-7 from Basic Protocol 2: 
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• DSAGEanalyze_nobsub.pl <Text_file from Step 1> 
• Example perl script for batching process to linux cluster: 
• DSAGEanalyze_bsub.pl <Text_file from Step 1> 
 3. For sample comparisons and normalization of the data, see Basic Protocol 2, step 
8. 
  
Support Protocol: Generation of Gene-Based Annotation Tables from Expanded 
Transcript Tables 
The steps outlined below can be used to make reference files for other species, or to 
remake the annotation tables to utilize updated gene annotations and/or genome 
assemblies. 
 
 1. Download a gene annotation table from the UCSC Genome Browser 
(http://genome.ucsc.edu/; also see UNIT 19.9). 
• Click the “Tables” link to proceed to the Table Browser. 
• Define genome and assembly. 
• Set group to ‘Genes and Gene Prediction Tracks'. 
• Set track to ‘UCSC genes'. 
• Set table to ‘knownGene’. 
• Set output to ‘selected fields from primary and related tables'. 
• Click ‘get output’. 
• Check the boxes for the first ten fields from knownGene (abbreviated: UCSC 
name, chr, strand, txstart, txend, cdsstart, cdsend, noexons, exonstarts, 
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exonends). 
• Check the boxes for ‘geneSymbol’ and ‘Description’ from kgXref. 
• Click ‘get output’ again. 
 2. To make a junctions file: 
makejunctions.pl <INPUT_UCSC_TABLE> <SPECIES> 
 3. To make a gene annotation file for gene expression using Refseq names: 
makeannexpression.pl <INPUT_UCSC_TABLE> <SPECIES> 
 4. Move the two generated files to the $DSAGE_TABLES folder. 
The <SPECIES> as named here should be used in Basic Protocol 2 and Alternate 
Protocol. 
   
Reagents and Solutions  
Use deionized, distilled water in all recipes and protocol steps. For common stock 
solutions, see APPENDIX 2; for suppliers, see APPENDIX 4. 
 Adapters 1 and 2 
• Adapter set 1: 
• 5’-p-TCGGACTGTAGAACTCTGAAC-NH2 
• 5’-ACAGGTTCAGAGTTCTACAGTCCGACATG 
• Adapter set 2: 
• 5’-CAAGCAGAAGACGGCATACGANN 
• 5’-p-TCGTATGCCGTCTTCTGCTTG- NH2 
 
Adapter oligonucleotides were obtained from Integrated DNA Technologies. 
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For each adapter set, anneal oligos (each at 50 µM with LoTE) in a thermocycler using 
the following program: 
• 2 min at 95°C 
• – 0.1°C/sec to 65°C, then 10 min at 65°C 
• – 0.1°C/sec to 37°C, then 10 min at 37°C 
• – 0.1°/sec to 25°C, then 20 min at 25°C 
• hold at 4°C. 
• Store annealed adapters at –20°C until use (up to 1 month). 
 Bind and wash (BW) buffer, 2× 
• 200 ml 5 M NaCl 
• 2.5 ml 2 M Tris-Cl, pH 7.5 (APPENDIX 2) 
• 1 ml 0.5 M EDTA (APPENDIX 2) 
• 296.5 ml ddH2O 
• Store up to several months at 4°C 
 Buffer C 
• 5 ml 10% SDS 
• 25 ml 2× BW buffer (see recipe) 
• 50 µl glycogen 
• 20 ml ddH2O 
• Store up to several months at 4°C 
• Heat prior use to dissolve SDS 
  
	   60	  
Buffer D 
• 25 ml 2× BW buffer (see recipe) 
• 1 ml 100× BSA (New England Biolabs) 
• 24 ml ddH2O 
• Store up to several months at 4°C 
Buffer E 
• 5 ml NEBuffer 4 (New England Biolabs) 
• 1 ml 100× BSA (New England Biolabs) 
• 44 ml ddH2O 
• Store up to several months at 4°C 
 LoTE buffer 
• 150 µl 1 M Tris-Cl, pH 7.5 (APPENDIX 2) 
• 20 µl 0.5 M EDTA (APPENDIX 2) 
• 49.83 ml ddH2O 
• Store up to several months at 4°C 
 MGB buffer, 10× 
• 8.3 ml 1 M (NH4)2SO4 
• 16.75 ml 2 M Tris-Cl, pH 8.8 (APPENDIX 2) 
• 3.35 ml 1 M MgCl2 
• 0.351 ml β-mercaptoethanol 
• 21.25 ml ddH2O 
• Store up to several months at 4°C 
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Commentary  
Background Information  
This unit describes a protocol for performing deep sequencing analysis of gene 
expression (DSAGE), a sequencing-based approach to quantifying gene transcript 
expression. Analog methods that involve hybridization of cDNA to microarrays of 
oligonucleotides have been used extensively to assess gene expression. However, 
such approaches only provide relative measurements with a small dynamic range, are 
limited to a set of known oligonucleotide probe sequences, and are hindered by 
hybridization biases (Draghici et al., 2006). In contrast, digital sequencing approaches 
to studying gene expression involve unbiased counting of observations of gene 
transcripts, offering quantification and more comprehensive analyses. Early 
sequencing-based methods, such as serial analysis of gene expression (SAGE; 
Velculescu et al., 1995; UNIT 25B.6), were limited in their depth to ~100,000 tags 
because of the high cost of Sanger dideoxy sequencing. We previously described 
polony multiplex analysis of gene expression (PMAGE), which utilizes a novel massively 
parallel sequencing method that facilitates a dramatic increase in sequencing 
throughput (to 5 million tags) and a substantial reduction in cost (Kim et al., 2007). 
DSAGE was adapted from PMAGE to use the Illumina Genome Analyzer II. Currently, 
15 to 25 million tags can be sequenced with one lane using the current Illumina 
analyzer, and this number is dependent only on the state of the sequencing technology 
used. 
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Analysis tools developed for RNA-seq (UNIT 4.11), Tophat (Trapnell et al., 2009), and 
Bowtie (Langmead et al., 2009) efficiently assign DSAGE tags to their corresponding 
genes. This approach facilitates the integration of DSAGE data with other data types, 
including RNA-seq and genomic variation, and is able to map tags across exon splice 
junctions. This approach provides flexibility in the reference transcriptome to which tags 
are mapped, permitting study of organisms with incomplete genomes or gene 
sequences. The protocol described in this unit uses transcript annotations from the 
University of California Santa Cruz (UCSC) Genome Browser (Kent et al., 2002; UNIT 
19.9), downloaded with the UCSC browser retrieval tool (Karolchik et al., 2004). 
   
Critical Parameters and Troubleshooting  
Table 2.1 describes some common problems encountered with DSAGE, as well as 
possible causes and recommended solutions. 
 
Table 2.1 Troubleshooting DSAGE Library Construction and Data Analysis 
 
Problem Possible cause Solution 
 
PCR for no-
ligase control 
produced an 88-
bp band 
Contamination from 
another library 
Replace affected reagents. Keep 
separate bench areas (and materials) 
for pre- and post-amplification 
reactions. 
The 66-bp pre-
amplification 
library is not 
visible 
Low yield Use the marker to excise the 66-bp 
product. 
No signal for low-
expressing genes 
 
 
 
 
 
 
Low-complexity library or 
insufficient sequence 
depth 
 
 
 
 
 
Check activity of enzymes and 
purification steps. The amount of 
material before amplification 
correlates with the complexity of the  
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     Table 2.1 
 
(Continued)  
library. A total of 10-15 cycles should 
be sufficient for amplification. 
Genes in the 
gene profiles 
display mostly 
null values 
Genome assembly used 
for alignment may not 
match the annotation 
tables 
Make sure that the genome assembly 
used for alignment matches the 
assembly of the reference tables. The 
reference tables provided with the 
analysis package are for assemblies 
hg19, mm9, and galGal3. 
No signal for a 
gene that is 
expressed in the 
tissue 
A small number of 
mRNAs do not have an 
NlaIII site 
Verify that the gene has an NlaIII site 
by retrieving the mRNA sequence 
 
Gene profiles of 
similar biological 
 
Poor RNA quality 
 
Use RNA with RNA integrity number 
(RIN) > 8 
samples do not 
correlate strongly 
Library may not be 
uniformly amplified 
Keep amplification cycles within the 
exponential range 
 Low-complexity library Increase yield (see above) 
 Contamination from 
another library 
See above 
Some program 
commands fail to 
return an output 
Software may be 
incorrectly set up. Also 
insufficient memory or 
other problems with the 
computing node. 
Test-run software using a small 
dataset 
 
 
The key element in constructing a DSAGE library is the starting quality of the RNA. RNA 
with an RNA Integrity Number (Agilent) greater than 8 may be used for optimal results. 
The yield depends not only on the quality and quantity of the RNA used, but also on the 
state of the materials. An indicator of the yield is the presence of the 66-bp pre-
amplification library, which is expected to be visible on the polyacrylamide gel after 
SYBR green staining. It should be noted that inability to visualize the band should not 
prompt discontinuation of the library preparation. In that case, the marker may be used 
to excise the band, carefully avoiding contamination with adapter dimer. 
 
Contamination of the pre-amplified library with an amplified library can have magnified 
effects. Since DNA is stable at room temperature, avoiding such contamination requires 
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maintaining a separate lab bench area to be used when processing the amplified library. 
Similarly, the instruments used for the amplified library (including refrigerator and 
freezer areas) should be marked as “post-PCR” and avoided when handling pre-
amplified libraries. Any materials can be tested for contamination by performing the 
PCR amplification reaction as described for the no-ligase control. 
 
The amount of the library obtained following amplification depends on the final 
amplification step and extraction from the gel. Cycles in the mid to upper part of the log-
phase of the reaction should be sufficient to generate enough material to be used for 
sequencing (the cycles should never exceed the log portion of the reaction). Also, 
special care should be taken to crush the extracted polyacrylamide gel into fine pieces. 
If crushing is incomplete (i.e., the gel remains grainy), the process can be repeated. 
Lower-yield libraries may require additional cycles to amplify to sufficient levels for 
sequencing; however, the number of amplification cycles is not expected to exceed 15. 
Libraries requiring more amplification cycles would display low complexity when 
sequenced, indicating that the dynamic capture of the low-expressing genes would be 
compromised. Test the efficiency of the enzymes and purification steps. Note that NlaIII 
must be kept at –80°C for long-term storage (>3 months). 
 
The software package pre-requisites must be installed and tested according to the 
developers' instructions. Although we recommend using Tophat version 10, as it 
appears to function best on our cluster with 21-bp reads, later versions can also be 
tested and used. 
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If the libraries are constructed properly, technical replicates are expected to yield highly 
reproducible results (r > 0.99). Similar biological samples are also expected to strongly 
correlate, as biological noise can be minimized by pooling RNA from biological 
replicates. If the expression profiles of such samples do not strongly correlate, the 
possibilities of poor RNA quality, poor amplification, low complexity of the amplified 
library, and the presence of contamination should be addressed. 
 
As with PMAGE and SAGE, DSAGE requires the presence of an NlaIII site on the 
transcript. An NlaIII site is present on the majority of transcripts, enabling almost 
complete profiles to be generated. To verify, the mRNA sequence can be retrieved and 
queried for the NlaIII site. 
In this analysis protocol, it is strongly recommended that alignment not allow any 
mismatches between the tag and the reference genome used. As a consequence, 
perfect matches are used to construct the transcriptional profiles. A complication of this, 
however, occurs when a polymorphism is present on the tag, in which case the tag will 
not be able to align to the genome. This may become an issue when comparing 
samples of different biological origin. However unlikely, this can be detected by 
identifying the NlaIII site on the transcript and identifying polymorphisms using the 
UCSC Genome Browser. Alternatively, Bowtie and Tophat could align the reads while 
allowing one or two mismatches. 
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Anticipated Results  
The 66-bp library is expected to be visible on a polyacrylamide gel after SYBR Green 
staining when the yield of the previous reactions is optimal. For a library with good 
complexity, less than 15 cycles are required for amplification. The 88-bp amplified 
library should always be visible. Beyond primer dimers, nonspecific amplification 
products should not be present. 
 
Current Illumina sequencers are expected to sequence more than 10 million tags. As an 
example, the authors typically observe expression of >10,000 genes in the mouse heart. 
   
Time Considerations  
Library preparation is expected to take 4 days. Sequencing is expected to take ~3 days, 
not taking into account scheduling queues at the sequencing facility. Data analysis 
should be completed within 1 day, given that run time is 1 hr per sample and parallel 
processing can be used with a computer cluster. 
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Chapter 3. Construction of Normalized RNA-seq Libraries for Next-Generation 
Sequencing Using the Crab Duplex-Specific Nuclease:  
Published in Current Protocols of Molecular Biology (Curr Protoc Mol Biol. 2011 
Apr;Chapter 4:Unit4.12.). Reproduced with permission of Current Protocols and John 
Wiley & Sons, Inc. Copyright © 2011 by John Wiley & Sons, Inc. 
 
Danos C. Christodoulou, Joshua M. Gorham, Daniel S. Herman, J.G. Seidman 
 
This unit describes the generation of a normalized RNA-seq library for next-generation 
sequencing by utilizing the preference of the crab duplex nuclease (DSN) for digesting 
double-stranded, rather than single-stranded DNA (UNIT 5.12; also see Zhulidov et al., 
2004). In this approach (Basic Protocol), polyadenylated RNA is used to generate a 
complex RNA-seq library. The library is denatured and incompletely renatured, and then 
digested with DSN. The kinetics of DNA annealing are such that at any given time 
abundant DNA molecules are more likely to have re-annealed and become double 
stranded, while rare molecules are more likely to remain single stranded. Thus, 
preferentially digesting double-stranded DNA with DSN yields a library markedly 
enriched for more rare DNA species. Massively parallel sequencing of these normalized 
libraries allows for efficient and comprehensive assessment of the sequence and 
structure of the polyadenylated transcriptome. 
 
The first step in the construction of a normalized RNA-seq library is to make a high-
complexity RNA-seq library (i.e., a library that includes sufficient depth of sequence 
from all positions of all polyadenylated RNAs). This involves starting with ~40 to 400 ng 
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polyadenylated RNA from ~2 to 20 µg total RNA. This method should also be suitable 
for non-polyadenylated RNA, in which case the protocol would be started at step 5. The 
quality of the RNA is crucial and can be determined using a Bioanalyzer (Agilent) 
(Schroeder et al., 2006) or an agarose gel. All steps in the protocol are performed with 
an excess amount of reagents to ensure each reaction approaches completion. 
The resulting high-complexity RNA-seq library is amplified to generate 500 to 1200 ng 
DNA using 19- to 20-bp primers corresponding to the inner sequences of the Illumina 
Paired-End adapters. Normalization of the RNA-seq library is then achieved by 
denaturing and re-annealing at 68°C, followed by treatment with the duplex-specific 
nuclease (DSN). The annealing temperature of the resulting amplified RNA-seq library's 
adapter sequence is ~57°C, which minimizes nonspecific targeting by DSN. A second 
amplification and normalization is then performed. The normalized library is then 
amplified with the full-length Illumina paired-end primers. See Figure 3.1 for an overview 
of the library construction. 
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Figure 3.1 Normalized RNA-seq library construction. Illustration of the normalization process starting from 
a rare (gray) and abundant (black) RNA transcript.  
 
Materials 
• Dynabeads mRNA DIRECT kit (Invitrogen, cat. no. 610-12) containing: 
o Lysis/binding buffer 
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o Washing buffer B 
• DynaMag-2 magnet (Invitrogen, cat. no. 123-21D) 
• RNA, purified using TRIzol (Invitrogen, cat. no 15596-018) or RNeasy kit 
(Qiagen, cat. no. 74104) 
• Quant-iT RNA assay kit (Invitrogen, cat. no. Q32852) 
• 5× fragmentation buffer (see recipe) 
• 3 M sodium acetate, pH 5.7 
• Glycogen (Roche, cat. no. 10901393001) 
• 70% (v/v) and 100% ethanol 
• SuperScript III cDNA synthesis kit (Invitrogen, cat. no. 18080-051) containing: 
o 10 mM dNTPs 
o 0.1 M DTT 
o 10× RT buffer 
o RNase OUT 
o SuperScript III reverse transcriptase 
o Random hexamers 
o 25 mM MgCl2 
o E. coli RNase H 
• Second-strand buffer (Invitrogen, cat, no. 10812-014) 
• E. coli DNA polymerase I (Invitrogen, cat. no. 18010025) 
• QIAquick PCR purification kit (Qiagen, cat. no. 28104) containing: 
o Buffer EB 
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• End-It DNA End-Repair kit (Epicentre Biotechnologies, cat. no. ER81050) 
containing: 
o 10× End-repair buffer 
o ATP 
o dNTPs 
o End-repair enzyme mix 
• dATP (Roche, cat. no. 11051440001) 
• NEB2 buffer (New England Biolabs) 
• 3’->5’ KlenowExo (New England Biolabs, cat. no. M0212s) 
• Quick Ligation kit (New England BioLabs, cat. no. M2200L) containing: 
o 2× ligation buffer 
o Quick T4 DNA ligase 
• MinElute PCR purification kit (Qiagen, cat. no. 28004) 
• 50-bp ladder (New England Biolabs, cat. no. N3236L) 
• 25-bp ladder (Invitrogen, cat. no. 10597-011) 
• SYBR Gold (Invitrogen, cat. no. S-11494) 
• QIAquick Gel Extraction Kit (Qiagen, cat. no. 28004) 
• Phusion High-Fidelity DNA Polymerase (New England Biolabs, cat. no. F-530S) 
containing 5× HF Phusion buffer 
• Oligonucleotides (see Table 3.1) 
• SYBR Green I (Invitrogen, cat. no. S7563) 
• AMPure beads (Agencourt AMPure kit, cat. no. A29152) 
• Quant-iT dsDNA HS Assay kit (Invitrogen, cat. no. Q32851) 
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• 4% to 20% TBE gel (Invitrogen, cat. no. EC62252BOX) 
• 4× hybridization buffer (see recipe) 
• Duplex-specific nuclease (Evrogen, cat. no. EVN-EA001-KI01) containing: 
o 10× master buffer 
o DSN enzyme 
• EDTA 
• UV transilluminator 
• Vortex 
• 1.5-ml nonstick RNase-free microcentrifuge tubes (Ambion, cat. no. 12450) 
• Heat block or incubator at 61° to 73°C 
• Qubit fluorometer (Invitrogen, cat. no. Q32857) 
• Dark Reader Transilluminator (Clarechemical, cat. no. DR-88M) 
• Thermal cycler 
• Additional reagents and equipment for agarose gel electrophoresis (UNIT 2.5A) 
 
Table 3.1 Oligonucleotide Sequences 
 
Oligonucleotide Sequence 
 
PE adapter 1a 5’phosphate-GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
PE adapter 2a 5’ACACTCTTTCCCTACACGACGCTCTTCCGATCT 
Inner PE primer1 5’CACGACGCTCTTCCGATCT 
Inner PE primer2 
 
 
5’CTGAACCGCTCTTCCGATCT 
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       Table 3.1  
Final PE primer 1 
(Continued) 
5’AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT 
Final PE primer 2 5’CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCT 
 
 
  
To prepare the adapter, resuspend each adapter oligonucleotide to 200 µM using water or 
reduced Tris-EDTA buffer. Mix equal amounts of each adapter oligonucleotide. Using a thermal 
cycler, anneal using the program: 4 min at 95°C, –0.1°C/sec to 12°C, hold at 4°C. The annealed 
adapters can be stored at –20°C until use. 
 
 Stage I: polyA selection, RNA fragmentation, cDNA and second-strand synthesis, end 
repair, A-addition, adapter ligation, gel purification, and first amplification 
 Perform polyA selection 
 1. Vortex the oligo(dT) beads (Dynabeads) at a low speed to make homogeneous. 
Transfer 100 µl into a 1.5-ml tube (nonstick tubes are used throughout the 
experiment). Capture the beads by placing the tube on the DynaMag-2 magnet, 
pipet off most of the solution, and wash with 50 µl lysis/binding buffer (Dynabeads 
kit). Repeat the capture and liquid removal, and resuspend in 50 µl lysis/binding 
buffer. 
 2. Prepare the RNA on ice (previously extracted using an RNeasy kit or TRIzol and 
quantified) by adjusting the volume to 50 µl with ddH2O. Add 50 µl lysis/binding 
buffer, heat at 61°C in a heat block for 2 min, and immediately place back on ice. 
Transfer the RNA to the washed beads and mix by pipetting. Incubate the binding 
reaction 10 min at room temperature with gentle agitation. 
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 3. Capture the beads on the magnet and discard the supernatant. Wash twice with 200 
µl buffer B (Dynabeads kit). Wash once with 50 µl washing buffer B, discard the 
buffer, and resuspend in 20 µl ddH2O. Elute the RNA from the beads by incubating 
1 to 2 min at 73°C in a heat block. Immediately capture the beads on the magnet 
and transfer the eluate to a new tube and place on ice. 
It is critical not to exceed the 73°C temperature during elution to prevent extensive 
RNA degradation. 
 4. Perform a second round of polyA selection by repeating steps 1 to 3 using the 
eluate from step 3 in place of total RNA in step 2 (adjust the volume to 50 µl by 
adding 30 µl of ddH2O). As in step 3, elute into 20 µl of ddH2O and place the tube on 
ice. Measure the mRNA concentration with the Quant-iT RNA assay kit and the 
Qubit fluorometer using 1 µl of the eluate. 
At this stage, the mRNA can be stored at –80°C until use. 
 RNA fragmentation (optional) 
 5. Use 40 to 400 ng mRNA, bring to a volume of 16 µl with ddH2O, and add 4 µl of 5× 
fragmentation buffer. Incubate 2 to 5 min at 94°C in a thermal cycler and place on 
ice. 
 6. Precipitate the fragmented RNA by adding 8 µl 3 M sodium acetate, pH 5.7, and 1 µl 
of glycogen. Mix and then add 240 µl 100% ethanol. Vortex and incubate 30 to 50 
min at –20°C. Pellet the precipitated RNA by centrifuging 15 min at maximum speed 
(>12,000 × g), 4°C. Remove the supernatant and wash the pellet with 800 µl 70% 
ethanol. Recentrifuge for 2 min at maximum speed (>12,000 × g), 4°C, completely 
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remove the ethanol, and dry the pellet for a few minutes at room temperature. 
 Synthesize the first strand 
 7. If continuing from step 6, resuspend the RNA pellet in 30 µl random hexamers 
(SuperScript III cDNA synthesis kit) and place on ice. If continuing from step 4, add 
10 µl random hexamers to the polyA RNA to 30 µl. Add the following: 
• 8 µl 10 mM dNTPs 
• 2 µl ddH2O. 
Mix and incubate 4 min at 65°C in a thermal cycler. 
Place on ice and add: 
• 8 µl DTT 
• 8 µl 10× RT buffer 
• 16 µl 25 mM MgCl2 
• 2 µl RNase OUT 
• 6 µl SuperScript III RT. 
Incubate for 10 min at 25°C, 25 min at 42°C, 25 min at 50°C, and hold at 4°C in a 
thermal cycler. 
 Synthesize the second strand 
 8. Add the following as a mastermix (amounts per sample): 
• 204 µl ddH2O 
• 80 µl 5× Second-strand buffer 
• 12 µl 10 mM dNTPs 
• 4 µl RNase H. 
Mix and add 15 µl DNA polymerase I. Mix again. Incubate 2.5 hr at 16°C and hold 
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overnight at 4°C in a thermal cycler. Purify the resulting second-stranded product 
using a Qiagen PCR purification kit according to the kit's instructions. Elute with 90 
µl buffer EB. 
Following this step, the product can be stored overnight at 4°C or up to 6 months at 
–20°C. 
 Perform end repair 
 9. Using the end-repair kit, prepare a mastermix containing the following (amount per 
sample): 
• 20 µl 10× end-repair buffer 
• 20 µl 10 mM ATP 
• 20 µl dNTPs 
• 6 µl end-repair enzyme mix 
• 89 µl ddH2O. 
Add 110 µl of end-repair mix to the 90-µl sample eluate from step 8 and incubate at 
55 min 20°C and hold at 4°C in a thermal cycler. Use the QIAquick PCR kit to purify 
the sample and elute into 80 µl EB. 
 10. For A-tailing, prepare a mastermix containing the following and add to the sample: 
• 10 µl NEB2 buffer 
• 4 µl 5 mM dATP 
• 6 µl 3’-5’ KlenowExo. 
Incubate 1 hr at 37°C in a thermal cycler. Use the QIAquick PCR kit to purify the 
sample and elute into 44 µl EB. 
A complete reaction is critical as A-tailing facilitates the addition of an adenosine 
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overhang at the 3’ end, which prevents self-ligation during the next step. 
 Perform adapter ligation 
 11. First add 6 µl of 100 µM PE adapter and 56 µl 2× ligation buffer (NEB Quick 
Ligation kit) to the sample and mix. Add 6 µl quick ligase and mix well. Incubate 20 
min at room temperature. Use the Qiagen minElute PCR purification kit according 
to the manufacturer's instructions and elute into 10 µl EB. 
Double eluting by passing the first eluate through the same column is 
recommended. 
 Perform the gel purification 
 12. Add gel loading dye to the above eluate and run on a 2% agarose gel (UNIT 2.5A) 
using the 50-bp ladder. Stain the gel with SYBR gold (1:10,000) for 10 to 15 min at 
room temperature and visualize with the Dark Reader Transilluminator. 
SYBR gold offers improved sensitivity compared to ethidium bromide and the 
transilluminator avoids exposing the DNA to UV radiation. 
 13. Extract a 100-bp band size between 180- to 350-bp (Fig. 3.2A). Use the Qiagen Gel 
extraction kit according to the manufacturer's instructions to extract the DNA and 
elute with 25 µl buffer EB. Pass the eluate through the column to double-elute. 
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Figure 3.2 (A) Library excision from a 2% agarose gel stained with SYBR gold (step 12). Here, an 
180- to 280-bp fragment was excised. B-D. Aliquots from different stages of library preparation. (B) 
Amplified library prior to normalization (step 18), (C) library after one round of normalization (step 
21), (D) library after two rounds of normalization amplified with the final Paired-End primers (step 
22). 
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 Perform the first amplification 
 14. For each sample, prepare the following PCR mix: 
• 5 µl 5× HF Phusion buffer 
• 1 µl of 10 µM Inner primer 1 
• 1 µl of 10 µM Inner primer 2 
• 1.25 µl 10 mM dNTPs 
• 0.4 µl Phusion polymerase 
• 0.25 µl SYBR Green I (diluted 1:1000) 
• 15.6 µl ddH2O 
• 0.5 µl RNA-seq library (end-product of step 13). 
 15. Carry out the amplification in a thermal cycler using the following conditions: 
Initial step: 30 sec 98°C (initial denaturation) 
24 cycles: 10 sec 98°C (denaturation) 
 30 sec 59°C (annealing) 
 30 sec 72°C (extension) 
1 cycle: 5 min 72°C (final extension). 
 
 
Determine the optimal cycle number for the final PCR amplification by selecting the 
point before the real-time PCR reaction saturates. That is, use the graphed 
fluorescence versus cycle number from the real-time PCR. The optimal cycle 
number is at the end of the exponential phase but before the reaction reaches a 
plateau. 
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Choosing cycles within the exponential range facilitates uniform amplification of the 
library and minimizes amplification errors. 
 16. Use the sample generated in step 13 to create twenty replicate reactions prepared 
as in steps 14 and 15 (substituting SYBR green with ddH2O) with the number of 
cycles determined in step 15. 
This aims at amplifying about half the sample (the remainder can be saved to be 
used if needed to repeat the amplification or to make a nonnormalized library). 
 17. Following completion of the reaction, combine the product from all tubes. Save 1 to 
2 µl to be run on the polyacrylamide gel (step 18), and purify the remainder using 
2× volume AMPure beads according to the manufacturer's instructions. Elute with 
20 µl ddH2O. 
This setup creates enough material for normalization, while using most of the initial 
material for amplification. This aims at amplifying a high complexity library. 
 18. Dilute 1 µl from the purified product 1:4 with water. Use 1 µl of the diluted product to 
estimate the library concentration using the Quant-iT dsDNA HS Assay kit and the 
Qubit fluorometer. Run 1 to 2 µl of the diluted product on a 4% to 20% 
polyacrylamide gel (UNIT 2.5A; include a lane of a 1-µl aliquot from prior to the 
DNA purification). Stain with SYBR Gold (1:10,000) for 10 min and visualize using a 
UV transilluminator (Fig. 3.2B). 
It is critical that the library appears as a smear and not a discrete band. 
  
 
	   84	  
Stage II: Perform first normalization, second amplification, purification, and second 
normalization 
 19. Bring 500 to 1200 ng amplified DNA to a volume of 12 µl with ddH2O. Add 4 µl of 4× 
hybridization buffer, mix, denature at 98°C for 2 min and re-anneal at 68°C for 6 hr 
in a thermal cycler. 
 20. For this step always work near the thermal cycler and keep the sample on the 
thermal cycler at 68°C, except when spinning down the contents of the tube. First, 
prewarm the 2× master buffer (dilute from the 10× provided in the Duplex-specific 
nuclease kit) on the thermal cycler and add 20 µl to the sample. Mix and incubate 
for 10 min. Add 3 µl of DSN enzyme (reconstitute and test in accordance to the 
manufacturer's instructions), mix well, spin down with a microcentrifuge for a few 
seconds at room temperature, and incubate for 25 min at 68°C. Add 1 µl of 125 mM 
EDTA, mix well, spin down, and incubate for 5 min. Following this reaction, 
immediately place the tube on ice and freeze if needed. 
It is critical that the hybridization temperature (68°C) be maintained throughout this 
procedure. Note that the DSN enzyme may still be active—keep the reaction cold or 
frozen to avoid nonspecific degradation. 
 21. Follow steps 14 to 20 to re-amplify the library with the inner primers and re-
normalize. Use 1 µl of the product slurry from step 20 as the template. Before 
normalizing, run a 1-µl aliquot on a polyacrylamide gel. 
The library should appear as a smear and not a discrete band when run on a 
polyacrylamide gel (Fig. 3.2C). 
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Stage III: Final amplification and purification 
 22. Use the final PE primers to amplify the product from step 21. Follow steps 14 to 18 
to amplify the library using 1 µl of 5 µM final PE primer and 1 µl of the product slurry 
from step 21. Purify with 1.8× volume AMPure beads and elute with 25 µl ddH2O. 
Measure the concentration and assess the DNA library size as in step 18. 
When running on a polyacrylamide gel, the library should appear as a smear (Fig. 
3.2D). The higher size of the smear is due to the added sequences from using the 
full-length paired-end primers. 
 23. Submit the library for end-sequencing at a concentration recommended by the 
sequencing facility. 
   
Reagents and Solutions  
Use deionized, distilled water in all recipes and protocol steps. For common stock 
solutions, see APPENDIX 2 ; for suppliers, see APPENDIX 4. 
 Fragmentation buffer, 5× 
• 200 mM Tris acetate, pH 8.2 
• 500 mM potassium acetate 
• 150 mM magnesium acetate 
• Store up to 1 year at –20°C 
 Hybridization buffer, 4× 
• 200 mM HEPES, pH 7.5 
• 2 M NaCl 
• Store up to 1 year at –20°C 
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Commentary    
Background Information  
RNA-seq is transforming our understanding of transcriptomes by revealing important 
information about transcript diversity, sequence, and structure. Comparison of these 
RNA transcriptomes between various cellular states has also facilitated study of 
transcript function and regulation (Cloonan et al., 2008; Mortazavi et al., 2008; 
Nagalakshmi et al., 2008; Sultan et al., 2008; Wang, 2008; Tang et al., 2009; Trapnell et 
al., 2010). However, despite the improved power of next-generation sequencing 
technologies, the very broad dynamic range of gene expression has been an obstacle 
to studies of RNA transcript structural changes in genes expressed at low levels, such 
as transcription factors, which, even at low levels, are of profound physiologic 
importance. Sequencing-based strategies to assess expression profiles, such as Polony 
Multiplex Analysis of Gene Expression (PMAGE) and Deep Sequencing Analysis of 
Gene Expression (DSAGE; UNIT 25B.9 and Kim et al., 2007), have demonstrated that 
in the cardiac left ventricle the 50 most highly expressed genes, which consist of 
mitochondrial, structural, sarcomere, and energy production genes, comprise greater 
than 40% of the polyadenylated RNAs. In addition, the most abundant RNA can 
comprise as much as 10% of the polyadenylated RNAs. By contrast, low-expressing 
RNAs are often found to comprise as few as 1 molecule per million, indicating that the 
range of RNA transcript expression levels spans at least five orders of magnitude. This 
large range impedes comprehensive characterization of transcripts expressed at low 
levels. 
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Critical Parameters and Troubleshooting  
An important consideration in constructing a normalized RNA-seq library is the 
complexity of the library prior to normalization. Lower complexity libraries can still be 
normalized, but will result in non-uniform sequencing of lower-expressing genes, as well 
as a high number of sequenced duplicate reads. 
 
Library cross-contamination is a major concern in this procedure, because such 
problems will be exaggerated by the normalization and PCR amplification steps. 
Contamination can be minimized by physically separating amplification steps from post-
amplified products and washing any laboratory equipment that comes in direct contact 
with the libraries, especially gel chambers and gel excision equipment. 
 
RNA degradation is also a significant concern. During RNA isolation steps, significant 
effort is required to avoid RNA degradation. In addition to working quickly, keeping the 
RNA on ice and using RNase-free glass- or plasticware, RNase inhibitors can be added 
to the sample. The RNA should be handled at the indicated temperatures, as higher 
temperatures or prolonged incubation can increase degradation. Degradation during the 
polyA selection will result in loss of transcript 5’ sequences, because selection is 
performed using the 3¢ polyA tail. 
 
Confirm that the DSN enzyme is active within a week prior to use, per the 
manufacturer's instructions. Also, see Table 3.2 for other critical parameters and 
troubleshooting tips. 
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  Table 3.2 Troubleshooting for Normalized RNA-seq Library Construction 
 
Problem Possible cause Solution 
 
RNA reads are not 
uniform 
RNA degradation (the 5’ 
of the transcript is more 
susceptible since the 
polyA selection is done 
from the 3’ end) 
Start with high-quality RNA; use 
RNA with RNA integrity number 
>8; reduce fragmentation time; 
begin with a single RNA sample 
and work quickly. 
Excessive (>15) PCR 
cycles are needed for 
amplifying the library 
before the 
normalization step 
Low starting RNA 
concentration 
Test RNA concentration and 
quality at the beginning. 
 Poor library generation, 
perhaps due to inactive 
enzymes/reagents 
Start with a new batch of reagents 
 Wrong primers Make sure that the inner primers 
are being used for the first 
amplifications 
A discrete band 
appears instead of a 
smear 
Low complexity library 
or PCR cycles exceeded 
the linear phase 
Check reactions; carefully assess 
the number of the real-time PCR 
cycles needed to amplify the 
library. 
Coverage enrichment 
only affects 
moderately expressed 
genes 
Low complexity library Start with a greater amount of 
polyA RNA. Utilize more 
templates by setting up more 
amplification reactions. 
  If starting with total RNA, polyA-
select prior library construction. 
Gene expression 
profiles do not appear 
normalized 
Inactive DSN enzyme or 
another problem with 
the DSN reaction. In 
addition, the library may 
not have been 
sufficiently amplified. 
Test DSN enzyme activity 
according to the manufacturer's 
instructions. Assess the effect of 
DSN by including a no-enzyme 
tube (and compare overall 
digestion in the sample with real-
time PCR). 
Excessive number of 
cycles are needed to 
amplify the library 
after it was normalized 
(but not before 
normalization); if 
sequenced, low 
complexity library 
 
 
 
 
 
 
 
DSN may have 
degraded the library. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Make sure that the library is well 
denatured. Check the quality of 
the thermal cycler or increase the 
denaturing time. During 
normalization, do not allow the 
tubes to be at room temperature 
beyond the short time needed to 
centrifuge the contents. Always 
work on ice when setting up 
follow-up amplifications after 
normalization, as the DSN 
enzyme may still be active. Also, 
make sure the buffer  
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          Table 3.2 (continued)  
 
concentrations used during 
normalization are correct. 
Unexpected read 
sequences (e.g., from 
a different organism or 
unexpected genomic 
regions) 
Contamination Make sure the library is not 
contaminated with another library. 
Keep a separate area with 
equipment and reagents for work 
during the pre-amplification phase 
of the library. Use a negative 
control during the real-time PCR 
amplification and run on a gel to 
check if a curve is visible. 
 
 
   
Anticipated Results  
Amplification cycles are expected to be in the range of 8 to 12 cycles and 12 to 15 
cycles for the final amplification. When amplified within the exponential phase, by using 
real-time PCR, these products are expected to appear as a smear rather than as 
discrete bands, as in Figures 3.2B-D. The library smears resulting from the 
amplifications using the inner primers are expected to be smaller than the gel-extracted 
library size, since they only amplify the inner part of the universal adapter sequence. 
Following amplification with the long Illumina final primers, the library size is expected to 
increase (Fig. 3.2). 
In the normalized libraries, highly expressed RNA transcripts are expected to be 
decreased in proportion in the library by about 10-fold compared to their original 
proportion (the highest expressing gene is reduced 50× in proportion). Lower-expressed 
RNA transcripts are expected to be enriched ~10-fold. Additionally, some previously 
undetectable RNA transcripts and some pre-mRNAs are expected to be present at 
nonnegligible levels. Untranscribed regions of the genome should not be enriched, but 
may contain rare interspersed reads not exceeding 1 to 2 reads depth. 
	   90	  
   
Time Considerations  
The RNA-seq library preparation takes ~4 days and normalization and final amplification 
takes ~3 days. 
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ABSTRACT 
Rapid advancement of next generation sequencing technologies has made it possible to 
study expression profiles of microRNAs (miRNAs) comprehensively and efficiently. We 
have previously shown that multiplexing miRNA libraries by barcoding can significantly 
reduce sequencing cost per sample without compromising library quality [Alon et al. 
2011, Vigneault et al 2012].  In this unit, we provide a step-by-step protocol to isolate 
miRNAs and construct multiplexed miRNA libraries.  We also describe a custom 
computational pipeline designed to analyze the multiplexed miRNA library sequencing 
reads generated by Illumina-based technology. 
 
INTRODUCTION 
miRNAs are short, 17-25 nucleotide non-coding RNAs that have emerged as critical 
regulators of gene expression in various physiological and pathophysiological 
processes [Mendell and Olson, 2012] due to their ability to influence the 
stability/translation of a large number of RNAs.  Our understanding of roles of miRNAs 
and their targets has been aided by miRNA expression profiling studies. While high-
throughput platforms including multiplex PCR and microarrays have proven to be 
valuable tools, next generation sequencing technology has quickly emerged as the 
preferred platform for studying miRNA expression.  One of the advantages of next-
generation sequencing is the ability to pool and sequence multiple samples in one lane 
of a sequencer, significantly lowering costs, without compromising the ability to 
construct comprehensive expression profiles for every assessed sample. 
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A typical miRNA library construction protocol involves 3’ and 5’ adapter ligation to 
miRNAs, followed by reverse transcription to generate cDNA libraries which are then 
amplified by PCR and purified by gel extraction prior to sequencing [Motameny et al. 
2010].  Multiplexing can be achieved by addition of barcodes (unique nucleotide tag 
sequences incorporated into the adapter or PCR primer) during library construction. 
However, barcodes on the adapter confer bias during ligation and thus must be 
avoided, whereas barcodes/indexes introduced during the amplification step is a safe 
alternative (Alon et al., 2011). 
 
One of the challenges of next generation sequencing is to sift through large data sets of 
millions of short reads generated by sequencers requiring computational analysis. 
Reads from miRNA sequencing are first processed to remove the 3’ adapter sequences 
and then matched to the reference sequence for identification of mature and/or novel 
miRNAs.  Identifying miRNAs with differential expression among samples by quantifying 
the number of reads per miRNA helps infer relevant biological processes. 
 
The purpose of this unit is to provide a step-by-step protocol of total RNA extraction to 
generation of miRNA exression profiles in tissues of interest.  First, we describe a 
protocol to isolate miRNAs and construct multiplexed miRNA libraries for Illumina 
sequencing (Alon et al 2011, Vigneault et al, 2012: CPHG Unit 11.12.1-10).  Next, we 
describe a custom bioinformatics pipeline designed to construct comprehensive miRNA 
expression profiles and assess differential expression between samples. Any measured 
changes can be quantified with precision as each miRNA is expected to be sampled a 
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large number of times during this process. [Although this pipeline is tested for Illumina 
reads, it can be adapted for any other platform.] 
 
BASIC PROTOCOL 1: 
ISOLATION OF TOTAL RNA CONTAINING miRNAs 
Total RNA containing miRNAs can be isolated from tissues either by 
Trizol/Phenol/Chloroform extraction or with commercially available kits.  One important 
determinant when choosing a commercially available RNA isolation kit is whether they 
retain small RNAs (<200 nucleotides).  We have successfully used Ambion’s miRVana 
miRNA isolation kit to isolate good quality total RNA, specifically from mouse heart 
tissue.  Before starting isolation, make sure to clean all equipment and bench-top with 
RNase Zap and frequently change gloves to prevent any RNase contamination. 
 
Materials 
RNase Zap (Ambion, cat. no AM9780) 
RNAlater (Qiagen, cat. no. 76106) 
RNase-free 1.5 ml microcentrifuge tubes  
RNase-free tips  
miRVana miRNA isolation kit (Ambion, cat. no. AM1560) 
ACS grade 100% Ethanol 
Microcentrifuge 
Bioanalyzer 2100 (Agilent) 
 
	   97	  
 
1. Isolate total RNA according to manufacturer’s protocol (miRVana isolation kit or 
Trizol).   
 
We recommend isolating RNA from fresh tissue or tissue stored in RNAlater.  For good 
quality RNA, the time between tissue dissection and RNA isolation should be 
minimized. We prefer homogenizing with steel beads using TissueLyser (Qiagen) as it 
allows processing of several samples simultaneously, and prevents cross-contamination 
between samples. Alternatively, if TissueLyser is not available, we prefer homogenizing 
using rotor/stator type homogenizer; however, equipment should be thoroughly cleaned 
between processing of different samples to prevent contamination.  If the tissue will not 
be immediately used for RNA isolation, it should be snap-frozen in liquid nitrogen and 
stored at -80 C.  When isolating RNA from frozen tissue, tissue should first be grinded 
to powder using prechilled mortar/pestle with liquid nitrogen to prevent thawing of tissue 
before lysis. Basic Protocol 2 for miRNA library construction works well on total RNA, 
but if enrichment is desired, an aliquot of total RNA should be saved for quality control 
and miRVana kit can be used to enrich for miRNAs. Although we have not directly 
compared expression profiles prepared from miRNA-enriched vs. total RNA, there may 
be some differences and we recommend that when different samples are compared, 
they should be prepared with the same method to prevent any bias. 
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2. Confirm quality of RNA. 
 
We strongly recommend that RNA quality is confirmed by Bioanalyzer (Agilent) and we 
have observed that RNA with RNA Integrity Number (RIN) >8 provides high quality 
libraries.  Alternatively, RNA quality may be checked by running an agarose gel to 
visualize 28S and 18S RNA. A 2:1 ratio of 28S to 18S indicates good quality RNA. 
 
3.        Store RNA in small aliquots at -80 C. 
 
Repeated freeze-thaw of RNA should be avoided to minimize RNA degradation, as 
degraded fragments can adversely affect multiple steps and possibly introduce biases. 
 
 
BASIC PROTOCOL 2: 
MULTIPLEX microRNA LIBRARY CONSTRUCTION FOR ILLUMINA SEQUENCING 
 
[Basic Protocol 2 has previously been published and incorporated from Vigneault et al in 
Current Protocols in Human Genetics, CPHG Unit 11.12.1-10] 
 
This procedure describes a method for constructing multiplexed miRNA libraries. A 
miRNA library is made (Figure 4.1) from each RNA sample by 3’ adapter ligation, 5’ RT 
primer annealing, 5’ adapter ligation, reverse transcription, and PCR amplification. 
Although the forward PCR primer is the same, a different reverse PCR primer with a 
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unique barcode is used for each RNA sample. The different libraries can then be pooled 
into a single sequencing reaction at the end of the library construction. The following 
instructions are for the preparation of one sample, so users must scale-up according to 
the specific number of samples they are preparing. All incubations are conducted in a 
thermal cycler.  
 
Materials 
RNase Zap (Ambion, AM9780)  
Nuclease-free water (Ambion, AM9937)  
Starting RNA 
10x T4 RNA Ligase 2tr Buffer (Enzymatics, L607) 
3’ rApp-adapter (see Table 4.1) 
100% DMSO (Sigma, D9170)  
RNase Inhibitor (Enzymatics, Y924L)  
RT primer (see Table 4.1) 
5’ RNA adapter (see Table 4.1) 
ATP (Enzymatics, N207-10-L)   
T4 RNA Ligase 1 (Enzymatics, L605L)  
dNTPs (Enzymatics, N205L)  
Superscript III First-Strand Synthesis System (Invitrogen, 180080-051)  
Phusion High-Fidelity DNA Polymerase (NEB, M0530S)  
BCmiRNA_PCR1 (see Table 4.1) 
BCmiRNA_PCR2_BC (see Table 4.1) 
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AgencourtAMPure XP 5 mL Kit (Beckman Coulter Genomics, A63880)  
E-Gel EX Gel, 2% (Invitrogen, G4020-02)  
70% (v/v) ethanol 
25 bp Ladder (Invitrogen, 10597-011)  
100 bp Ladder (Invitrogen, 15628-019)  
MinElute Reaction Cleanup Kit (Qiagen, 28204)  
Agilent High Sensitivity DNA Kit (Agilent, 5067-4626)  
Thermal Cycler (for all incubations) 
E-Gel I-Base Power System (Invitrogen, G6400)  
E-Gel Safe Imager Real-Time Transilluminator (Invitrogen, G6500)  
Dynamag-2 Magnet (Invitrogen, 123-21D)  
Recommended: Iceless Cold Pack (Eppendorf 022510509)  
Recommended: Agilent 2100 Bioanalyzer 
Optional: Nanodrop Spectrophotometer 2000 
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PROCEDURE 
Ligation of 3’ adenylated adapter 
Make sure to clean surfaces and instruments with RNase Zap and maintain RNase-free 
conditions throughout the protocol. While as few as 100 ng of total RNA is sufficient, we 
recommend starting with at least 1 µg of total RNA (one can also use the equivalent 
fraction of enriched for small RNAs if desired). We recommend verifying RNA quality 
using the Agilent Bioanalyzer RNA nano or pico chip and using samples of RIN value of 
7 or above. 
 
1| Dilute the starting RNA to 200 ng/µL in nuclease-free dH2O, if possible. 
2| Set up a ligation reaction in a 200 ul PCR tube. 
Component Volume (µl) Final 
Concentration 
200 ng/µlRNA in dH2O 5 1 µg total 
10x T4 RNA Ligase 2tr 
Buffer 
1 1x 
10 µM 3’rApp-adapter 1 10 pmoles total 
100% DMSO 1 10% 
3| Denature for 30 sec at 90°C, then for at least 30 sec at 4°C.  
4| Add the following directly to the ligation reactions on ice: 
Component Volume 
(µ l) 
Final Concentration 
RNase Inhibitor (40 U/µl) 0.5 2 U/µl 
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T4 RNA Ligase 2tr (200 U/ 
µl) 
1.5 30 U/µl 
5| Incubate for 1 h at 22°C. 
 
We recommend using Enzymatics buffer, as its composition gave us significantly 
higher yield than other commercially available T4 RNA ligase 2 truncated buffers. 
 
Annealing of RT primer  
6| Add the following directly to each reaction on ice: 
Component Volume 
(µ l) 
Final 
Concentration 
10µM RT Primer 1 10 pmoles total 
 
The final amount of RT primer must be at equimolar ratio (10 pmoles) with the 
starting amount of 3’rApp-adapter (10 pmoles) for each sample. 
 
7| Incubate for 30 sec at 90°C, then for 5 min at 65°C, then for at least 30 sec at 4°C.  
 
Ligation of 5’ RNA adapter 
8| Prepare the 5’ RNA adapter by incubating ~5µl in a 200 ul PCR tube at 70°C for 2 
min, then 4°C for at least 30 sec. 
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An excess of volume is prepared to account for evaporation and facilitate the 
pipetting of the proper volume at the next step. 
9| Spin down the ligation mixture by centrifuging 10 sec at ~2000 x g, room 
temperature, using a microcentrifuge and add the following reagents directly to it: 
Component Volume 
(µ l) 
Final 
Concentration 
10 mM ATP 1.5 1µM 
10 µM 5’ RNA Adapter 1 10 pmoles total 
T4 RNA Ligase 1 (20 U/µl) 1.5 2 U/µl 
10| Incubate for 1 h at 20°C. 
 
Reverse transcription of captured MicroRNAs 
The previous steps result in a reaction volume of 15 µl. Only 5µl is used in the 
subsequent RT-PCR step, and so the remaining can be stored (-80°C) as a backup 
(highly recommended) for two more runs. However, the rest of the protocol below can 
be scaled up 3 times and the full 15µl may be processed at once if you need to achieve 
higher yield (for example, when starting with lower amounts of RNA). 
11| Prepare the following reactionin a 200 ul PCR tube: 
Component Volume (µl) Final Concentration 
Ligated miRNAs 5 -  
5x First strand buffer 2 1x 
12.5mM dNTP mix 0.5 625 µM 
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100mM DTT 1 10 mM 
RNase Inhibitor (40 U/µl) 0.5 2 U/µl 
Superscript III (200 U/µl) 1 20 U/µl 
12| Incubate for 30 min at 48°C. 
As the RT primer was annealed earlier, do not denature or conduct an annealing 
cycle at this stage but go directly to the reverse transcriptase incubation temperature 
(48°C, as shown above). 
Limited PCR Amplification 
13| Prepare the PCR reaction in a 200 ul PCR tube: 
Component Volume (µl) Final concentration 
dH2O 27  To 50 ul total 
Reverse Transcribed-
miRNAs 
10 - 
5x HF buffer 10 1x 
25mM dNTPs 0.5 0.5 mM 
25 µM BCmiRNA_PCR1 1 0.5 µM 
25 µM 
BCmiRNA_PCR2_BC* 
1 0.5 µM 
Phusion DNA pol. (2 U/µl) 0.5 1 U 
 
BCmiRNA_PCR2_BC* refers to the bar-coded primer,where for each unique starting 
RNA sample a unique bar-code primer needs to be used (see Table 4.1). To limit 
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bar-code / samples aerosol contamination, it is recommended to only open and 
close one tube of primer at a time. 
 
14| Cycle the PCR reaction as follows in a thermal cycler: 
1- 98°C for 30 sec 
2- 98°C for 10 seconds 
3- 60°C for 20 seconds 
4- 72°C for 20 seconds go to step 2, 11 more times 
5- 72°C for 5 min 
6- 4°C pause 
 
The number of cycles can be varied according to the amount of microRNA present in 
the starting sample. In our hands, a total of 12 cycles generally results in the best yield 
while limiting unnecessary cycling. We recommend not exceeding 15 cycles as this will 
increase non-specific background amplification and reduce optimal yield of the desired 
products. Instead, additional starting RNA should be prepared in parallel and combined 
at the final stage to increase yield. 
 
PCR Clean-Up with AMPure XP beads 
15| Transfer PCR reactions to a new 1.5 mL tube. 
16| Vigorously mix the AMPure XP beads and then add 90 µl of beads to each 50 µl 
PCR reaction. Pipet the beads slowly. 
17| Vortex for 30 seconds, and then incubate on bench for 5 min. 
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18| Quick spin, and place on the magnetic rack for 5 min. 
19| With the tubes still on the magnet, aspirate and discard the liquid from the reaction. 
20| With the tubes still on the magnet, add 400 µL 70% EtOH to the beads and leave for 
30 sec. Then discard the 70% EtOH. 
21| Repeat the previous step for a second wash. 
22| Quick spin on a microfuge to collect last traces of EtOh. Put tubes back on magnet 
and remove any last drops of EtOH at the bottom of the tube. 
23| Leave the tube open to air dry for 2 min. 
24| Remove the tube from the magnet and add 45 µL of nuclease-free water. 
25| Vortex for 30 sec. 
26| Place the tubes on the magnet and leave for 1 min. 
27| With the tubes on the magnet, transfer 42 µL to new 1.5 mL tubes. 
 
Gel extraction of microRNA library 
28| Prepare a 2% Agarose Gel EX following the manufacturer’s protocol. 
29| Dilute the 25 bp and 100 bp ladders 1:20 in water and load 20 µL of each. 
30| Split each microRNA library prepared above across 2 lanes by loading 20 ul per 
well. 
31| Run the gel for 14 minutes on the Invitrogen I-Base using the 2% E-Gel settings. 
32| When the run is complete, take a picture of the gel. 
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The migration patterns of DNA on E-gels are affected by the total amount and salts 
present in the loaded sample, and sometime one may observe a shift in migration of 
the expected product in relation to the ladder. 
 
33| Pry open the E-Gel by cracking open each side. 
34| Using a clean razor blade for each sample, cut between 125 and 175 bp to capture 
the two dominant miRNA bands. 
35| Gel extract using the Mini Elute Qiagen Gel-Extraction Kit following the 
manufacturer’s protocol, conducting the final elution in 15 ul of dH2O 
 
Melt the gel bands at 37°C instead of the recommended 55 °C. The MinElute columns 
have a tendency to trap residual EtOH from the wash steps. To avoid this issue, dry 
spin the column for 1 minute at maximum speed and then turn the column 180 degrees 
and repeat the spin for another 1 minute. Then transfer the column to a recovery tube 
and leave the column open for 3 min to air dry prior to adding the elution buffer. 
 
Library QC and Mixing 
36| The library can now be mixed at equimolar concentration, prior to submission for 
sequencing. We strongly recommend analyzing the quality and concentration of 
each final library using the Agilent Bioanalyzer DNA high sensitivity chip in order to 
combine the different libraries at equimolar ratios into a single multiplexed library. 
Although less accurate, a Nanodrop spectrophotometer would also work to a decent 
degree for this step if an Agilent Bioanalyzer is inaccessible. For high throughput 
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project with high amount of samples, the Bioanalyzer can be used to combine the 
libraries prior to gel extraction.  
37| Submit library for sequencing using standard Illumina genomic primer or Truseq 
primer with 75 bp single-read.  Alternatively, a custom indexing primer can also be 
used if desired (Table 4.1). 
 
BASIC PROTOCOL 3: 
 
BIOINFORMATICS ANALYSIS OF MULTIPLEXED miRNA LIBRARY SEQUENCING 
DATA  
Analysis pipeline presented here aims at measuring miRNA expression and assessing 
differential expression between samples.  It also provides an efficient way to construct 
comprehensive miRNA expression profiles. Here, we use annotated mature miRNAs 
deposited regularly in miRBase as a reference. (http://www.mirbase.org).  In our 
analysis pipeline, first, the 3’ adapter sequences are removed and then the reads are 
assigned to separate output files based on different barcodes used. Next, miRNAs are 
identified by aligning the reads to miRBase (version18) (Kozomara A and Griffiths-
Jones S 2011) and the reads are tallied to generate total counts for each miRNA.  
Finally,  statistical significance (p-value) between 2 or more samples is calculated to 
generate differential expression profiles.  The analysis programs are written in Perl and 
the steps described can be performed through the command line.   The workflow of 
analysis pipeline is shown in Figure 4.2.   
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Materials 
Hardware pre-requisites: 
        Linux, Unix or Mac OS X installed computer or Cygwin with Windows.  
  A computer cluster may not be necessary although recommended. 
  No significant memory requirements. 
 
Software pre-requisites: 
        Perl v5.10.0 
        BioPerl module for SAGE comparison 
        Text-editor program (e.g. TextWrangler) 
 
Analysis package: 
         Analysis programs are all written in Perl and can be found at 
 http://seidman.med.harvard.edu/fgs/software/mirna_soft/mirna_soft.tar.gz 
 
Files needed: 
          Sequence file in FASTQ format (e.g. reads.fastq)  
         A FASTQ file from a sequencing run includes 4 lines per read.  The first line 
starts with “@” followed by a unique identifier, second line includes the 
sequencing read, third line may contain additional sequencing run 
information and fourth line includes the quality scores for each nucleotide in 
the sequencing read.  
       mature.fa.gz (http://www.mirbase.org/ftp.shtml) 
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       reads.fastq is provided in the package for a test run. 
 
1. Download and install the following programs: 
a. Perl:  http://www.perl.org 
b. BioPerl module for SAGE comparison by algorithm described by Audic and 
Claverie (1997) http://search.cpan.org/~scottzed/Bio-SAGE-Comparison-1.00/  
Once downloaded, unpack the module.  Type: 
 
 tar xvfz Bio-SAGE-Comparison-1.00.tar.gz 
 
Then, add the module’s path to the PERL library environment variable.  Use 
PERL5LIB for Perl 5.  Type: 
 
 export PERL5LIB=/location_to_downloaded_module/Bio-SAGE-
Comparison-1.00/lib 
 
c. The analysis package: 
http://seidman.med.harvard.edu/fgs/software/mirna_soft/mirna_soft.tar.gz 
which includes the following scripts: separatebarcodes.pl, 
countreads_mirna.pl and cmp_mirna.pl .  To unpack the modules, type:  
 tar xvfz mirna_soft.tar.gz 
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2. Download the latest mature.fa.gz from http://www.mirbase.org/ftp.shtml containing 
all the mature miRNA sequences. 
 
3. Remove the 3’ adapter sequence and separate reads into individual files by 
barcode. Type: 
 
perl separatebarcodes.pl  reads.fastq 
 
A section of separatebarcodes.pl is shown below and MUST be modified according to 
the samples/barcodes/adapter used by using a text editor program such as 
TextWrangler (Mac) or equivalent. 
 
 
my $adaptor="ACGGGCTAATATTTATCGGTGGAGC"; ## specific adapter sequence 
my %barcodes = (                                                             
 CGTGAT => "Sample1", #BC1 ## these are associating each barcode with  
 ACATCG => "Sample2", #BC2 ## corresponding sample 
 GCCTAA => "Sample3", #BC3 
 TGGTCA => "Sample4", #BC4 
 CACTGT => "Sample5", #BC5 
 ATTGGC => "Sample6", #BC6 
 GATCTG => "Sample7", #BC7 
 TCAAGT => "Sample8", #BC8 
); 
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This perl script is designed to analyze the sequencing reads obtained from multiplexed 
miRNA libraries constructed using the adapters and PCR amplification primers shown in 
Table 4.1.  Usually, the first part in the sequence corresponds to the miRNA sequence.  
The miRNA sequence is then followed by the adapter sequence 
“ACGGGCTAATATTTATCGGTGGAGC”, which is followed by a 6-nucleotide barcode (Table 
4.1, bold-underlined).  First, the script opens the sequencing file reads.fastq, removes 
the 3’ adapter, identifies each sample by barcode and creates one output file per 
sample based on the barcodes. The user is advised to confirm the output file by ‘less’ or 
‘more’ command or by opening with any text-editor program.  The output file should look 
like Samplename.fq. If Illumina TruSeq small RNA adapters/primers are used, the user 
can easily modify the script to reflect the appropriate adapter and barcode sequences.   
 
4. Uncompress  mature.fa.gz  downloaded from miRBase. Type: 
 
gunzip mature.fa.gz 
 
Open the file mature.fa and select the entries corresponding to the appropriate 
species (e.g. mus musculus for mouse). Save as species_mature.fa in a separate 
file to use in the next step.  Alternatively, from the command line type (for mouse): 
 
grep –A1 musculus  mature.fa > mouse_mature.fa  
 
	   113	  
      Open and verify final file. 
 
5. Match the reads to reference miRBase and tally the counts of   
reads per microRNA to generate an expression profile per sample.  Here, output files 
generated in step 3 are used as input.  Type: 
 
     perl countreads_mirna.pl species_mature.fa OUTPUT_STEP3 
 
This perl script is applied to each output file from step 3 (OUTPUT_STEP3, e.g. 
Samplename.fq) after processing with the first script.  First, the sequences shorter than 
17 nucleotides are eliminated.  Then, the script aligns the sequence to reference mature 
miRNA sequences, downloaded from miRBase. There are 2 output files created per 
sample: The first file Samplename.m contains information for aligned miRNAs: “miRNA 
name” “Sequence of the miRNA”, “Unique matches”, “Multi-matches”. “Unique matches” 
are reads matching specifically to that miRNA out of the total list. “Multi-matches” 
includes reads with multiple reference miRNA sequences and are not subsequently 
used. To maximize read counts and incorporate reads from putative isomiRs, an 
unmatched full length read is trimmed at the ends before another matching attempt. The 
second file Samplename.unm contains the reads that did not match to any miRNA in 
the miRBase. These unmatched reads often contain small inserts that may not qualify 
as miRNAs such as fragmented RNAs or bad quality reads, and any unannotated novel 
miRNAs.  To identify novel miRNAs, Samplename.unm can be matched to other 
species’ miRNA sequences using the method described here, and they can also be 
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aligned to the reference genome depending on the uniqueness and length of the 
sequence. 
 
The output file can be confirmed by using ‘less’ or ‘more’ commands or can be opened 
by any text-editor program. 
 
6. Normalize and compare expression profiles of miRNAs.  Type: 
 
perl cmp_mirna.pl Samplename_1.m Samplename_2.m …Samplename_8.m 
 
This script can be applied to two or more output files from step 5 to make a comparison.  
The read counts are normalized to counts per million by dividing the total read counts of 
a miRNA by the total read counts of the sample and multiplying this number by 106. The 
script uses a Bayesian comparison based on Audic and Claverie (1997) to calculate the 
p-value.  The output file for two samples will include  “miRNA ID”,  “Tag Sequence“ 
“Normalized Counts for Sample1”, “Normalized Counts for Sample2”, ”Raw reads for 
Sample 1”, “Raw reads for Sample2”, and “p-value” , while for more samples, it will 
include corresponding additional fields. 
 
7. Analyze the final output file.   
 
We generally consider p-value ≤ 0.01 as an appropriate cut-off given the list of miRNAs. 
However, more stringent cut-off may be used.  
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COMMENTARY 
Background Information 
Owing to the development of high-throughput methods to study miRNA expression 
profiles, there has been an exponential increase in the amount of data generated in the 
miRNA field over the last decade. Compared to microarray or qPCR-based miRNA 
exression profiling techniques, next generation sequencing technology offers several 
advantages, including high sensitivity to measure miRNA levels over a wide dynamic 
range, ability to identify novel miRNAs and to detect miRNA expression levels in 
species for which complete genomes are not yet available.  In addition, next-generation 
sequencing is able to detect miRNAs that differ by just one nucleotide [Pritchard et al.  
2012]. Last but not the least, next-generation sequencing allows multiplexing of samples 
by tagging libraries with barcodes during library preparation.   
 
Even though different sequencing platforms require different protocols and 
adapters/primers, they typically follow similar steps. First step of miRNA library 
construction is to capture miRNAs using specific adapters.  miRNAs have a 5’ 
phosphate and a 3’ hydroxyl group as a result of RNAse III activity of Drosha and Dicer.  
To prevent self ligation and circularization of miRNAs during adapter ligation, pre-
adenylated 3’ adapters are used with truncated T4 RNA ligase 2 (which does not 
require ATP).  Next, miRNAs are ligated to a 5’ adapter, which contains the binding site 
for sequencing primer.  The resulting adapter-captured miRNAs are reverse transcribed 
with a primer complementary to the 3’ adapter to generate cDNA library.  To provide 
enough yield for sequencing, cDNA library then needs to be PCR-amplified.  Finally, the 
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amplified library is gel extracted and quality-checked prior to sequencing.  To sequence 
multiple libraries in one lane of a flow cell, each miRNA library can be barcoded by 
including a unique tag sequence as part of the adapter or PCR amplification primer 
during construction. However, we and others have reported previously that including 
barcodes in the adapter sequence creates significant ligation bias [Alon et al. 2011, 
Hafner et al. 2011], e.g. same biological sample tagged with 2 different barcodes show 
significant differences in miRNA expression levels, presumably as a result of bias by T4 
RNA ligase-mediated ligation [Zhuang et al. 2012, Jayaprakash et al. 2011].  In the 
current protocol, we add barcode to each library during PCR amplification step, which 
helps avoid any ligation bias and therefore, provides a significant advantage (Alon et al 
2011, Vigneault et al. 2012 CPHG Unit 11.12.1-10).  With this method, up to 12 libraries 
can be prepared in parallel and sequenced in one lane of Illumina Genome Analyzer 
/HiSeq. 
 
Several bioinformatics tools have been developed to analyze miRNA sequencing reads 
(Li et al. 2012) and they generally follow similar steps with some variations.  Typically, 
after the first step of 3’ adapter removal, the sequences are aligned against a reference 
sequence to identify annotated miRNAs as well as novel ones. One of the important 
parameters for bioinformatics analysis of miRNA sequencing reads is the alignment 
criteria.  Several groups have identified isomiRs (variants from the reference) for a given 
mature miRNA and reported that the most abundant isomiR may not always be same as 
the mature miRNA [Morin et al. 2008, Wyman et al. 2011, Lee et al. 2010]. IsomiRs, 
which differ mainly at the 3’ end, and to a lesser extent at the 5’ end, may also include 
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nucleotide substitutions or 3’ non-template addition of nucleotides. While some studies 
have quantified the most abundant isomiR as the most representative of the miRNA 
level [Morin et al. 2008], others have quantified miRNAs with 100% length and 
sequence match with mature miRNA [Wang et al. 2009]. In a recent study, expression 
levels of isomiRs were reported to highly correlate with that of annotated mature 
miRNAs [Cloonan et al. 2011]. While isomiRs may well be biologically relevant, 
abundance of some isomiRs above that of mature miRNA may also result from T4 RNA 
ligase bias in capturing small RNAs [Hafner et al. 2011, Jayaprakash et al. 2011, 
Zhuang et al. 2012]. Since the biological significance of isomiRs is largely unknown and 
their biogenesis is not understood, currently, our analysis pipeline counts miRNAs with 
exact matches as well as those with some variation to the annotated mature miRNA in 
miRBase (version 18). Our analysis pipeline also keeps a separate file of reads not 
aligning to miRBase, and these reads can be mapped against the reference genome to 
identify putative novel miRNAs. 
 
Critical Parameters and Troubleshooting 
One of the most critical parameters for a high quality library is the quality of starting 
RNA.  Therefore, it is important to maintain an RNAse-free workspace throughout RNA 
isolation (Basic Protocol 1) and library construction protocol (Basic Protocol 2: steps 1-
12).  Another critical parameter is to avoid contaminating pre-amplified library with 
amplified library, as even the slightest contamination will have detrimental effects for 
downstream analysis.  Therefore, we recommend designating separate equipment, 
reagents and bench-space for all the steps prior to PCR-amplification of libraries (Basic 
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Protocol 2: Step 14) as “pre-PCR” and for all the steps after PCR-amplification as “post-
PCR”. We strongly recommend including a “no-ligase” control reaction (where T4 RNA 
ligase is omitted) and processing in parallel to the experimental samples to assess for 
any possible contamination, which will be evident after PCR amplification step.  If an 
amplified library is detected in the control, the prepared libraries should be discarded 
and new reagents should be used to start over.  Therefore, to prevent wasting of 
reagents, we recommend that oligos, and all other library construction reagents are 
stored in small aliquots. 
 
During library construction, 3’ and 5’ adapters are used in excess to ensure efficient 
capture of miRNAs and to prevent their self-circularization.  As a result, the adapters 
can ligate to each other and the undesired adapter-adapter dimer band is often 
observed in the agarose gels during library preparations.  In this protocol, annealing the 
RT primer to the 3’ adapter-ligated product, prior to ligation of 5’ adapter, can 
significantly reduce the adapter dimer formation and therefore, we do not expect to see 
the dimer band (114bp) on an agarose gel.  However, if an adapter dimer band is 
observed, one or two rounds of denaturing PAGE extractions should be performed (as 
described in Alon et al. 2011) to remove the adapter dimer and to prevent unnecessary 
sequencing of this undesired ligation product. Denaturing gel extraction ensures that 
any dimer fraction that may have annealed to the full-length library fragments is 
removed.   
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Another critical parameter is to quantify the final multiplexed library yield (Basic Protocol 
2: step 36) right before submission, as low yield library may fail to cluster. If low yield 
libraries are obtained, we recommend starting with either more RNA, or preparing 
multiple libraries from the same RNA in parallel.  In addition, PCR amplification cycles 
can be increased (but not more than 15, as this may result in low complexity library). 
 
The multiplexed miRNA libraries prepared according to our protocol can be sequenced 
on Illumina Genome Analyzer II or HiSeq using either the standard Illumina primer for 
genomic libraries or primer for Truseq.  It is critical to perform a 75bp single-read 
sequencing to ensure that insert miRNA (<30bp), 3’ adapter (25bp) and barcode (6bp) 
are all sequenced.   Alternatively, the libraries can be sequenced using a custom 
indexing primer (Table 4.1), however, this may be more expensive, as the whole flow 
cell has to be cycled twice, which may not be required for other lanes in the flow cell. 
 
For bioinformatics analysis of sequencing reads, we highly recommend that for the first-
time analysis, the user runs each script successively to generate the final output file.  
This will ensure that each module is running successfully, and if there is a problem, it 
will be easier to identify.  If an extremely high-throughput is desired, the steps can be 
automated for more efficient processing of the sequencing data.  
 
Even though we expect strong correlation (r >0.99) in technical replicates, in order to 
minimize differences due to technical variation, we recommend that the libraries that are 
to be directly compared, be handled and prepared in parallel. It is also expected that the 
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biological replicates show a strong correlation; however, if they do not, this can be due 
to several factors including poor RNA quality (we recommend RIN>8), low complexity 
library (we recommend increasing the library yield before the PCR amplification step by 
starting with more RNA or processing multiple libraries from the same RNA and keep 
PCR amplification to no more than 15 cycles) or contamination with another library. We 
have also observed that there is a strong correlation between libraries prepared from 
“pooled” RNA samples (pooling RNA from 3 biological replicates) and average of 3 
libraries prepared separately from RNA of 3 biological replicates.  We believe that 
“pooled” RNA approach can help reduce the biological variation, allow user to pool RNA 
when sources are limited and also reduce the cost of sequencing.   
 
As a first follow-up experiment, we highly recommend that the sequencing data is 
confirmed by quantitative RT-PCR.  There are several commercially available qPCR kits 
to quantify miRNAs, and in our hands, Applied Biosystems’ stem-loop qPCR primers 
(Taqman) work well.  
 
Anticipated Results 
Technical and/or biological replicates are expected to have a strong correlation (r >0.99) 
with sequence counts ranging from 10 to 100000< counts per million.  We advise 
ignoring miRNAs with less than 10 counts per million in all the groups being compared, 
since they can be due to sequencing errors.  
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Time Considerations 
Total RNA isolation can be completed in under 1 hour for few to several samples.  The 
library construction protocol of up to 12 samples can be completed in one day.  The 
bioinformatics analysis can be completed within one to several hours depending on the 
number of total sequences.  
 
Table 4.1. List of all oligos used for multiplexed miRNA library preparation for Illumina 
sequencing.  Bold-underlined bases represent 6-nucleotide barcodes. (Alon et al. 
2011). 
 
Name                            Sequence (5’-3’) 
BCPCR_3'rApp-adapter                   /5rApp/ACGGGCTAATATTTATCGGTGG/3SpC3/ 
BCPCR_5'RNA-adapter                   rUrCrCrCrUrArCrArCrGrArCrGrCrUrCrUrUrCrCrGrArUrCrUrC 
BCPCR_RT primer                            GCTCCACCGATAAATATTAGCCCGT 
BCPCR_PCR1         
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT 
BCPCR_PCR2-BC1         
CAAGCAGAAGACGGCATACGAGATCGTGATGCTCCACCGATAAATATTAGCCCGT 
BCPCR_PCR2-BC2                            
CAAGCAGAAGACGGCATACGAGATACATCGGCTCCACCGATAAATATTAGCCCGT 
BCPCR_PCR2-BC3         
CAAGCAGAAGACGGCATACGAGATGCCTAAGCTCCACCGATAAATATTAGCCCGT 
BCPCR_PCR2-BC4                            
CAAGCAGAAGACGGCATACGAGATTGGTCAGCTCCACCGATAAATATTAGCCCGT 
BCPCR_PCR2-BC5                            
CAAGCAGAAGACGGCATACGAGATCACTGTGCTCCACCGATAAATATTAGCCCGT 
BCPCR_PCR2-BC6         
CAAGCAGAAGACGGCATACGAGATATTGGCGCTCCACCGATAAATATTAGCCCGT 
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Table 4.1 (continued) 
BCPCR_PCR2-BC7         
CAAGCAGAAGACGGCATACGAGATGATCTGGCTCCACCGATAAATATTAGCCCGT 
BCPCR_PCR2-BC8                 
CAAGCAGAAGACGGCATACGAGATTCAAGTGCTCCACCGATAAATATTAGCCCGT 
BCPCR_PCR2-BC9                            
CAAGCAGAAGACGGCATACGAGATCTGATCGCTCCACCGATAAATATTAGCCCGT 
BCPCR_PCR2-BC10                          
CAAGCAGAAGACGGCATACGAGATAAGCTAGCTCCACCGATAAATATTAGCCCGT 
BCPCR_PCR2-BC11                          
CAAGCAGAAGACGGCATACGAGATGTAGCCGCTCCACCGATAAATATTAGCCCGT 
BCPCR_PCR2-BC12                          
CAAGCAGAAGACGGCATACGAGATTACAAGGCTCCACCGATAAATATTAGCCCGT 
BC_Custom_Indexing                      ACGGGCTAATATTTATCGGTGGAGC (optional) 
 
Notes: All oligonucleotides can be ordered through Integrated DNA Technologies (IDT; 
http://www.idtdna.com).  The oligos should be ordered with HPLC purification. The 
adenylated adapter can be ordered from IDT, or if on a budget, made as previously 
described (Vigneault, Sismour, & Church, 2008). 
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Figure 4.1.  Schematic for miRNA library construction for next-generation sequencing 
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Figure 4.2. Workflow for bioinformatics analysis of multiplex mRNA library sequencing 
data 
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Chapter 5. Genome-wide transcriptional start-site analyses identifies Four-and-a-half LIM 
domains protein 1 as a modifier of hypertrophic cardiomyopathy: 
Manuscript is in submission. Supplemental tables and supplemental image data can be 
provided upon request. Supplemental text and figures are in Appendix 1. The supplemental 
software package can be downloaded from the following location: 
http://seidman.med.harvard.edu/fgs/software/RNAseq-5pr-package.tar.gz 
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We report a transcriptome sequencing (RNA-seq) strategy that detects genome-wide 
changes in transcript levels and start-site usage.  Using this methodology we 
interrogated the pathologic responses to sarcomere gene mutations in hypertrophic 
cardiomyopathy (HCM).  We show that Four-and-a-half LIM domains protein 1 (Fhl1) 
undergoes robust transcriptional activation and altered start-site usage in HCM, resulting 
in a distinct protein isoform in myocytes.  The Fhl1 isoform switch is conserved in mice 
and humans with primary and secondary cardiomyopathies.  By analyses of genetic 
ablation of Fhl1 in mice with HCM, we demonstrate that Fhl1 transcriptional activation 
and isoform switching has salutary effects on cardiomyopathy.  These data implicate 
Fhl1 as an adaptive modifier to cardiomyopathy stress.  Encoded on chromosome X, 
stress-induced transcriptional changes in Fhl1 may contribute to gender differences in 
the clinical severity of HCM. 
 
Pathogenic mutations produce broad changes in cell biology, in part by impacting gene 
expression.  Changes in gene expression occur by altering transcription levels and/or diversify 
the transcriptome through the alternative use of 5’ start-sites, alternative exon splicing, and 
differential use of polyadenylation sites.  Several methods for high throughput sequencing of 
cDNAs have been recently developed to interrogate the transcriptome (RNAseq)1-4. 
 
By modifying RNAseq protocols, we describe a strategy to define genome-wide assessment of 
RNA levels and structure, inclusive of quantitative assessments of 5’ start-site usage.  Using 
this methodology we studied the mouse cardiac transcriptome in a model of human hypertrophic 
cardiomyopathy (HCM) and identified transcriptional diversity in Fhl1 that influences the clinical 
severity of this disorder.  
 
	   130	  
We first optimized steps for constructing cDNA libraries for RNAseq to minimize RNA or cDNA 
fragmentation and we incorporated random hexamer priming to complete cDNA synthesis 
(Supplemental Methods).  After adding adaptors, we used size selection and cDNA polarity to 
enrich the sequencing of small fragments that include transcripts with 5’ ends (Fig. 5.1a, 
Supplemental Fig. 5.1 and Supplemental Fig. 5.2). The gene expression profiles derived from 
this approach, termed as 5’RNA-seq, had high technical reproducibility (Supplemental Fig. 
5.3).  Additionally, there was a strong correlation (r=0.9) between the gene set with altered 
transcription (including low expression genes) identified by sequenced based transcriptional 
profiling and this RNAseq methodology (Supplemental Fig. 5.4 and Supplemental Table 5.1). 
 
To identify differences in start-site usage among isoforms, we developed computational 
approaches that detect shifts in read-depth distribution at the start-site regions of genes and to 
quantify the extent of change in start-site usage (Fig. 5.1b and Supplemental Methods). The 
sum of instances with detected shifts at 5’ ends was converted into a RNAseq score for each 
gene. We provide this bioinformatic approach as open-source, free to use computational tools 
with configurable parameters to provide concurrent computation of gene expression profiles, 
quantification of 5’ changes, and a tool for obtaining image data of gene profiles (Supplemental 
software package). 
 
We used two strategies to validate this approach for defining alternative start-site usage. First 
we visually assessed RNAseq reads in 800 genes and confirmed that reads corresponded to 
alternative transcriptional start-sites annotated in UCSC Genome browser (Supplemental 
Image Data). The rank order of RNAseq scores significantly correlated with alternative start-site 
usage (P-value=1.07E-11 calculated with ROC curve analysis; Supplemental Fig. 5.5). We 
also performed 5’ RACE on genes RNAseq scores (between 30 and 257), which validated an 
alternative start-site usage in each. 
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We employed 5’RNAseq to assess the transcriptional diversity in the hearts of MHC403/+ mice, 
which carry a human HCM missense mutation, Arg403Gln, in the myosin heavy chain gene5-7. 
Male MHC403/+ mice recapitulate the human disease and develop increased left ventricular (LV) 
wall thickness (hypertrophy) with myocyte hypertrophy and disarray as well as increased 
amounts of myocardial fibrosis.  Prior comparison of the LV transcriptomes from adult male 
wildtype and MHC403/+ mice showed hundreds of genes with altered levels of expression8,9.  We 
observed very high correlation (r=0.9) in the altered expression (increased or decreased) of 
genes defined by RNAseq (Supplemental Table 5.1) and these earlier studies.  
 
From the UCSC Genome browser we identified 8,000 annotated mouse genes that have more than 
one transcriptional start-site (Supplemental methods).  Genome-wide assessment of start-site 
usage by 5’RNAseq analyses of MHC403/+ hearts revealed 97 genes with scores ≥20, indicative of 
significant fold changes in transcriptional start-site usage (Fig. 5.1c, Supplemental Table 5.2, 
Supplemental Table 5.3 and Supplemental Image Data).  Most genes with altered start-site usage 
also had increased expression in MHC403/+ compared to wildtype hearts (P value = 1.1E-74 calculated 
by Chi-square). 
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Figure 5.1 RNA-seq without RNA or cDNA fragmentation allows sensitive assessment of start-
site changes. (a) Enhanced sequencing at 5’ ends of transcripts and directional information. 
Reads with transcript reference (left panel) or complement strand (right panel) plotted at 
positions normalized for transcript length. (b) Bioinformatic approach assessing changes in 
distributions at gene start-sites.  (c) Distribution of fold of start-site changes in HCM 
distinguishes Four-and-a-half LIM domains protein 1 having the most robust change. Plotted are 
changes for genes that are statistically significant (p-value<0.05 calculated by Chi-square). 
 
Fhl1, which encodes four-and-a-half LIM domains protein-1 had both markedly increased 
expression in MHC403/+ hearts and exhibited the most significant change in start-site usage (69-
fold; P value= 4.8E-24).  Fhl1 transcriptional profiles (Fig. 5.2a) revealed that wildtype mice 
primarily used a start-site (denoted bFhl1, basal) located 5’ to an alternative start-site (denoted 
sFhl1, stress-induced) that was predominant in MHC403/+ mice.  Since normalized transcriptional 
read-depths are similar for bFhl1 in wildtype and MHC403/+, the markedly increased Fhl1 
expression in mutant hearts reflects use of the sFhl1 start-site.  The sFhl1 translational site is 
predicted to incorporate 16 amino acids (NCBI accession: NP_001070830) that are absent from 
bFhl1 transcripts. 
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We performed 5’RACE to validate and provide semi-quantitative assessment of Fhl1 start-site 
usage in the hearts of wildtype and MHC403/+ mice (Fig. 5.2b and Supplemental Fig. 5.6).  
Dideoxy sequences of 5’RACE fragments indicated that bFhl1 predominated in wildtype hearts 
and sFhl1 in MHC403/+ hearts (Supplemental Fig. 5.7, which shows 5’RACE data confirming 
5’RNA-seq start-site usage assessment).  To confirm the impact of transcriptional changes in 
Fhl1 on protein expression, we also performed Western blots of cardiac lysates. Consistent with 
increased and altered start-site usage, the Fhl1 protein levels were markedly increased (Fig. 
5.2c) and slightly larger (~2KDa) in lysates from mutant compared to wildtype mice.  
  
We considered whether altered Fhl1 expression in MHC403/+ hearts reflected transcriptional 
changes in myocytes, which express the mutant sarcomere protein, or in non-myocytes, which 
proliferate and contribute to increased fibrosis in MHC403/+ hearts.  RNAseq of isolated myocytes 
and non-myocytes revealed Fhl1 expression in both cardiac cell populations (Supplemental 
Table 5.3), albeit at lower levels than was detected in whole hearts.  Non-myocytes isolated 
from wildtype or MHC403/+ mice expressed comparable levels of bFhl1 transcripts and no sFhl1 
transcripts. In contrast, the Fhl1 transcriptional profiles from myocytes paralleled those in whole 
hearts: MHC403/+ myocytes had higher Fhl1 levels, with predominantly sFhl1 transcripts in 
comparison to wildtype myocytes (Fig. 5.2d and Supplemental Fig. 5.8). 
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Figure 5.2 Marked upregulation of a low-expressing isoform in myocytes accounts for Fhl1 
transcriptional switch and results in increased protein levels. (a) Normalized read depth for the 
Fhl1 gene locus. bFhl1 (basal) and sFhl1 (stressed-induced) isoforms are indicated. sFhl1 is 
markedly upregulated in MHC403/+ hearts. (b) Fhl1 5’RACE product run on an agarose gel is 
consistent with RNA-seq data (Analysis shown in Supplemental Fig. 5.7). (c) Western blot 
showing Fhl1 increased levels in HCM. A mild increase in the size of the upregulated protein is 
accounted by an earlier translational start in the sFhl1 isoform. (d) Fhl1 start-site switch occurs 
in the myocytes (myo). sFhl1 isoform is not expressed in non-myocytes (fib) from either wild-
type or MHC403/+ hearts. Reads were normalized to total reads per million excluding 
mitochondrial reads. (Grey bar: bFhl1, Black bar: sFhl1.) 
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We hypothesized that induction of the sFhl1 isoform might have functional roles in the myocyte 
responses to HCM mutations.  To consider the consequences of Fhl1 ablation in HCM mice we 
crossed Fhl1-null mice that express lacZ under the endogenous Fhl1 promoter10 with MHC403/+ 
mice.  As Fhl1 is encoded on chromosome X we studied hemizygous male (Fhl1lacZ) and 
homozygous female (Fhl1lacZ/lacZ) mice.  The LV dimensions and function of adult male and 
female Fhl1-null mice were comparable to wildtype controls (Table 5.1).  In contrast male 
MHC403/+/Fhl1lacZ mice and female MHC403/+/ Fhl1lacZ/lacZ mice developed more marked HCM 
hypertrophy and histopathology than MHC403/+ mice (Table 5.1). 
 
Table 5.1. Echocardiographic measurements of left ventricular wall thickness (LVWT). To 
assess the effect of Fhl1 in hypertrophy in the presence of a sarcomere mutation, p-values were 
computed (student’s two-tailed t-test). Shown also are Fhl1 null control mice that do not develop 
hypertrophy (one-tailed test). 
          
Genotype Sex Number LVWT 
Pvalue (vs 
MHC403/+) 
MHC403/+ M 12 0.99±0.33  
MHC403/+/Fhl1 null M 12 1.31±0.37 0.039 
Fhl1 null M 6 0.72±0.05 0.036 
     
MHC403/+ F 11 0.95±0.39  
MHC403/+/Fhl1 null F 7 1.44±0.38 0.017 
Fhl1 null F 4 0.77±0.05 0.2 
     
Wild-type M 3 0.70±0.03  
Wild-type F 3 0.69±0.09  
     
          
 
Using RNA-seq we confirmed that compound wildtype/ Fhl1lacZ/lacZ and MHC403/+/ Fhl1lacZ/lacZ 
mice maintained the Fhl1 transcriptional patterns defined in wildtype and MHC403/+ mice, 
respectively (Supplemental Fig. 5.9).  We also confirmed that both the bFhl1 and sFhl1 
transcripts encoded lacZ sequences in frame (not shown).  β-galactosidase (β-gal) assays 
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detected low baseline expression in cardiac tissues from compound wildtype / Fhl1lacZ/lacZ mice. 
Young, pre-hypertrophic male MHC403/+/ Fhl1lacZ mice had minimal and focal β-gal expression in 
myocytes adjacent to fibrotic regions, that was demarcated by Sirius red (Fig. 5.3a, bottom left 
panel).  Consistent with increased transcription of the sFhl1 isoform, male MHC403/+/ Fhl1lacZ 
mice with overt hypertrophy had robust myocyte β-gal expression.  
 
As prior studies identified increased Fhl1 expression in the LV of mice with pressure overload 
hypertrophy11 as well as in human HCM hearts12 we examined Fhl1 transcriptional changes in 
other cardiac pathologies. LV RNAseq data from LV samples derived from patients with HCM, 
dilated cardiomyopathy, aortic stenosis, and heart failure each showed increased Fhl1 
expression due to induction of sFhl1 transcripts (Fig. 5.3b).    
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Figure 5.3  Fhl1 upregulation co-occurs with fibrosis, and is universally found in other 
cardiomyopathies. (a) Histologic analysis co-localizes Fhl1 upregulation (blue staining from β-
gal with X-gal) with fibrosis (red staining from collagen with Sirius red). All sections carry β-gal 
driven by the Fhl1 promoter. Experimental sections were processed in parallel with control 
sections. (upper left) Control mouse with wild-type myosin heavy chain and no upregulated Fhl1 
or fibrosis. (lower left) Prehypertrophic MHC403/+ exhibit Fhl1 upregulation in myocytes in the 
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(Figure legend 5.3, Continued)  prehypertrophic scar region. (upper right) Fhl1 upregulation in 
myocytes co-occurs with fibrosis in MHC403/+ with overt hypertrophy. (lower right) Magnified 
region of upper right panel (indicated in a yellow box). (Bars: 0.5mm for left and upper right 
panels; 0.05mm for lower right panel). (b) Transcriptional switch from sFhl1 upregulation occurs 
in primary and secondary cardiomyopathies. WT: wild-type; N: normal; HCM: hypertrophic 
cardiomyopathy; DCM: dilated cardiomyopathy; LVH: pressure-overload left ventricular 
hypertrophy; CHF: congestive heart failure. The isoform switch is conserved between mouse 
and human where it also occurs between the corresponding isoform orthologues. Grey bar: 
bFhl1, Black bar: sFhl1. Libraries from mouse samples were constructed from pooled replicates; 
human samples were constructed from individual replicates. 
 
 
Collectively these data demonstrate that sFhl1 transcriptional changes are a prominent myocyte 
response to HCM and other pathologies.  Increased Fhl1 expression in myocytes, by activation 
of an alternative transcriptional start-site, implicated sFhl in either the pathogenic pathways 
triggered by a sarcomere gene mutation or in compensatory responses to HCM.  Gene ablation 
studies clarified this ambiguity; MHC403/+/ Fhl1-null mice had significantly worse HCM, therein 
defining induction of sFhl1 as beneficial to myocytes.  Moreover, as this transcript was 
increased in a wide range of cardiac pathologies, sFhl1 induction appears to be a common 
adaptive response to myocyte stress.   
 
Recently three rare human variants in Fhl1 have been hypothesized to cause HCM13 that 
exhibited incomplete penetrance in females and an associated skeletal myopathy in some 
males.  That Fhl1-null mice had normal cardiac dimensions and function challenges this 
conclusion, and raises the possibility that human variation in Fhl1, in particular those that cause 
a loss of function, prevent the salutary effects that increased levels and isoform switching of 
Fhl1 have on cardiac disease.  
  
Given its location on chromosome X, the protective effects of sFhl1 may contribute to the 
gender-specific outcomes observed in HCM. Although autosomal dominant sarcomere gene 
mutations cause HCM, clinical studies demonstrate more severe LV dysfunction in men 
compared to women with HCM14, and more sudden death events during athletic participation. 
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Our data shows a strong trend whereby a large fraction of female MHC403/+/ Fhl1-null mice 
develop severe hypertrophy (43% females versus 25% males; LVWT ≥ 1.6), even though due to 
the small sample size it does not reach statistical significance. We speculate that dosage of 
sFhl1 and perhaps human variation contributes to these important clinical differences. 
 
In conclusion, development of a novel RNAseq strategy that provides genome-wide 
ascertainment of transcriptional diversity uncovered dynamic regulation of sFhl1 in HCM 
myocytes.  To our knowledge, sFHl1 represents the first beneficial genetic modifier in HCM.  We 
suggest that elucidation of the differences in protein-protein interactions conveyed by the 16 
amino acids and identification of molecules that activate sFhl warrants further study. 
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METHODS 
Model Organisms. All study protocols were approved by the Animal Care and Use Committee 
of Harvard Medical School.  aMHC403/+ in 129/SvEv and Fhl1 null in Black Swiss crossed mice 
were studied. Newly designed primers for genotyping Fhl1 null mice were used: 
AAACCAGGCAAAGCGCCATTCG, GGCCCACTTGTCCTCTGAGTCAGC, 
TGCAAGGGGTCCCTGCAGTAGTGA. Used in the same reaction, the combination of these 
three primers produce a ~370bp (wild-type), ~510bp (knock-out) bands. Cyclosporin A (CsA) 
was administered in chow (100mg CsA/100g chow) to accelerate hypertrophic remodeling9. 
Hypertrophic MHC403/+ mice were used (assessed by echordiography) unless when indicated. 
 
Echocardiographic studies. Mice were anesthetized with an isoflurane vaporizer (VetEquip) 
and each limb was placed on the ECG leads on a Vevo Mouse Handling Table (VisualSonics 
Inc.) maintaining the body temperature at 37ºC during the study. Transthoracic 
echocardiography was performed using Vevo 770 High-Resolution In Vivo Micro-Imaging 
System and RMV 707B scan-head (VisualSonics Inc.) with the heart rate at 500-550 bpm. The 
images were acquired as 2D (left parasternal long and short axes) and M-mode (left parasternal 
short axis). Measurements averaged from 3 consecutive heart beats of M-mode tracings were 
used for LV end-diastolic diameter (LVEDD), LV end-systolic diameter (LVESD), and wall 
thickness (interventricular septum, IVS and left ventricular posterior wall, LVPW). LV fractional 
shortening (%) was calculated as follows: (LVEDD– LVESD)/LVEDD × 100. All 
echocardiographic measurements were done blinded to mouse genotype. 
 
RNA-seq library construction and analysis. To reduce biological variation, RNA was pooled 
from biological replicates. RNA-seq was performed as previously described with no RNA or 
cDNA fragmentation and without any normalization15. Uniform amplification of the cDNA library 
was achieved with amplification cycles before the reaction reached saturation determined with 
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qPCR. Following sequencing, alignment of reads was performed with Tophat16. Read-depth 
profiles were constructed with Tophat’s “wiggles” tool and values were normalized to total 
aligned reads and uploaded on the UCSC browser17 or IGV18. Read-depths shown here were 
adapted after visualizing on UCSC Browser. Gene expression profiles are constructed by 
tallying reads on gene loci and comparisons utilized a Bayesian p-value19,20. Samtools21,22 was 
used to generate and process binary alignment files. Plots of directional reads were generated 
by assigning gene reads to bins based on the position of the read on the transcript including 
upstream and downstream regions.  
 
Start-site analysis algorithm. For the genome with ‘m’ genes {x
  1, x   2, x   3 … x   !}, let’s define a 
typical gene model and mathematical algorithm.  Let’s say gene ‘x’ has ‘n’ isoforms and each 
isoform has a unique 5’ position (Fig. 5.1b).  
 
Let’s say total number of reads for gene ‘x’ is 
x!    for sample ‘a’ 
x!    for sample ‘b’ 
 
As shown (Fig. 5.1b), each isoform has a 5’ interval of 400 bp and let’s say each position has 
some read coverage and is represented as 
 
R!, !!  = {r   1, r   2, r   3 … r   400}!, !!  
 
where R!, !!   = vector of reads at each position in ith isoform for ‘x’ gene in ‘a’ sample. 
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We normalize each vector with corresponding total reads: 
 
NRD!, !!  = R!, !! /x!                 where  ‘a’ = sample ‘a’ 
     x = gene ‘x’ 
     x!   = total reads for gene ‘x’ 
     NRD!, !!  = normalized read depth for ith isoform   
 for gene ‘x’ in sample ‘a’ 
 
We calculate a normalized read-depth ratio (NRDR) vector: 
 
NRDR!!  = {NRD!, !! /NRD!, !! } = {nrdr   1, nrdr   2, nrdr   3 … nrdr   400}!!    
 
After calculating NRDR!! , we calculate p-values based on Bayesian test19. We get a p-value 
vector for ‘x’ gene at ‘i’ isoform: 
 
 P!!  = {p   1, p   2, p   3 … p   400}!!    
 
Using these NRDR!!  and P!! , we assign a binary vector to each isoform ‘i’ of gene ‘x’ using 
formula below, where ‘j’ is the position in the 5’ interval: 
 
 f(b
!, !! ) = { 1     if  nrdr!, !!  ≥  foldcut-off 
           or nrdr
!, !!  ≤ 1/foldcut-off 
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          AND p
!, !!  < p-valuecut-off 
                0       otherwise     } 
 
Using this function, we prepare a matrix of binary vectors for each isoform ‘i’ of each gene ‘x’ in 
the genome and assign a score S
  ! as below: 
 
   S
  !  = !!, !!!""!!!!!!!  
 
This way for each gene ‘x’ from the genome, we get a score vector for all ‘m’ genes: 
 
 S = {S
  !: ∀ x ϵ [1, m]} 
 
We implemented this mathematical concept using Perl as shown (Supplemental software 
package). 
 
Myocyte and non-myocyte isolation. Cells were isolated using the Langendorff heart 
preparation as previously performed9. In addition, the final myocyte pellet was resuspended in 
MEM with 5% FBS and 2mM L-glutamine and plated in laminin-coated culture dishes (in 2% 
CO2 incubator at 37°C). After a 1-hour incubation, cells were rinsed with sterile PBS to remove 
nonadherent cells and debris and TRIzol (Invitrogen) was added to extract total RNA according 
to manufacturer protocols. 
 
5’RACE. 5’RACE was performed using a commercially available kit (Ambion, cat#AM1700) with 
amplification performed using rTth DNA polymerase (Applied Biosystems, cat#N808-0188). For 
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Fhl1, an outer primer with sequence TCCAGATGTGATGGCCTTGTTGCACTT and an inner 
primer with sequence ACATGGTGCCCACCTTATAGCTGGA were used. 
 
Western blotting and histology staining. Western blot was performed as previously 
described using mice harboring another mutation (MHC719/+) that causes hypertrophic 
cardiomyopathy9. An Fhl1 mouse monoclonal antibody was used (Abcam cat. Ab58067). For 
histology, frozen sections were prepared and incubated with X-gal for 30 minutes. Sections 
were then washed in PBS, fixed in 4% PFA for 40 minutes, washed in PBS again, and stained 
with Sirius red as previously described23 and mounted with Permount. 
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CHAPTER 6 
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Chapter 6. Discussion: 
 Built upon the biological and engineering advancements of the past century, the 
recently developed ability to sequence millions of DNA fragments simultaneously with 
relative ease is revolutionary for the field of biology. This technological breakthrough 
creates opportunities to measure fundamental biological properties with unprecedented 
resolution, offering new avenues to investigate the underlying processes that are 
responsible for certain diseases. While the high throughput of DNA sequencing (now on 
the order of 100 million sequences at a cost of less than 3-4 thousand dollars and 
falling)3 allows for high resolution measurements, similar analysis of the transcriptome 
offers a substantial challenge, as transcripts are expressed in a very wide dynamic 
range (some transcripts are found at significant proportions while others of importance 
such as transcription factors are found in proportions as low as 1-2 copies per million) 
(Chapter 3). While transcripts comprising the mRNA are typically longer than 200bp, 
miRNAs are tiny, with sizes around ~20bp (Chapter 4). Thus, comprehensive 
sequencing of RNA species is currently not possible by using one method alone. 
 This dissertation is concerned with the development of approaches to query 
different aspects of the transcriptome offering the potential to provide new biological 
information. Deep sequencing analysis of gene expression (Chapter 2) offers the ability 
to quantify the dynamic range of gene expression. Normalization with the duplex-
specific nuclease offers the ability to dramatically increase the sequencing of low-
expressing transcripts by degrading the high-expressing species (Chapter 3). 
Additionally, sequencing of miRNAs also requires development of dedicated protocols 
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given the small size of miRNAs (Chapter 4). Although not pursued experimentally or 
discussed here further, additional work led to computational methods to compare exon 
read coverage, identify mutations in transcriptional data, and analyze ChIP-seq data. 
Lastly, gene expression changes can be assayed accurately with RNA-seq 
without RNA or cDNA fragmentation (Chapter 5). The chemistry of the library 
construction favors sequencing from the 5’ ends of transcripts, providing for a greater 
depth of sequencing at these regions. This is beneficial as it gives a specific signature 
of the location of the sequencing, resulting in another level of quality validation (in 
particular for low-expressing transcripts), as well as leading to the ability to assess 
changes at start-site usage. 
These methods can be applied to ubiquitous biological settings. Application of 
gene expression analysis on cells that were genomically edited or mouse hearts in 
which histone methylation was perturbed is briefly described (Appendix 2). 
Application of this new approach in Hypertrophic cardiomyopathy (HCM) led to 
the identification of Four-and-a-half LIM domains protein 1 (Fhl1) as the gene displaying 
the most marked change in start-site usage. This start-site usage change is very robust 
(~70 fold), is accurately conserved between mouse and human, and occurs in all 
cardiomyopathies assessed. Further, it co-occurs histologically with fibrosis which may 
explain why start-site change appears to be global in cardiomyopathy. Interestingly, 
Fhl1 genetic ablation worsens the hypertrophic response in mouse carriers of the 
sarcomere mutation. In other words, the sarcomere mutation in the absence of Fhl1 
expresses the HCM pathology more strongly, indicating that Fhl1 as an adaptive 
modifier of HCM.  
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The role of Fhl1 in HCM is contrary to the one identified in pressure overload 
hypertrophy, where Fhl1 ablation alleviated the hypertrophic response (Chapter 5). The 
root causes of pathologic hypertrophy in pressure overload and of HCM caused by a 
sarcomere mutation are different. While left ventricular hypertrophy caused by pressure 
overload is characterized by increased hemodynamic load, a sarcomere mutation 
results in enhanced biophysical properties of the contracting sarcomere. This would 
imply, assuming the two cardiomyopathies converge at later stages, that Fhl1 has a 
very early role in the pathology. Particularly, a sarcomere gene mutation in the early 
stages of HCM leads to enhanced myocyte contractile properties which results in 
disease, possibly through disturbance of energy homeostasis, i.e. overall energy 
depletion (Chapter 1). Fhl1, which is thought to act as a biomechanical sensor in the 
heart [1, 2], may inhibit the contractile properties of myocytes, an effect that would be 
beneficial in the context of an overactive sarcomere in HCM but not in pressure 
overload (Chapter 5). An association of Fhl1 with sarcomere components could result in 
energy transmission from the sarcomere to Fhl-mediated downstream signals. Another 
possible explanation is that Fhl1 insertion in the sarcomere could modify the myosin-
actin interaction [3], also resulting in slowing down of the overactive sarcomere.  Some 
evidence that Fhl1 mutations can exert effects on contractility has been shown [4]. If 
Fhl1 does not change the contractility of myocytes, its compensatory effect in HCM may 
be due to downstream signaling. This is supported by the identification of multiple 
binding partners including DNA [3, 5 - 9]. Thus, Fhl1 may also exert effects in multiple 
locations. As reviewed (Chapter 1), different pathways are thought to be mechanistically 
involved in the development of HCM and Fhl1 could be having unrecognized roles in 
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some of these pathways. Fhl1 mutations have been firmly associated with muscular 
diseases [10-20]. Evidence also supports a role of Fhl1 in the cardiovascular system [1, 
3, 21, 22]. 
This dissertation identifies Fhl1 as a compensatory modifier of HCM and 
discusses its possible modes of action. Generalizing this observation, a factor that 
brings the biophysical properties closer to physiological levels or alleviates downstream 
pathologic processes can be an adaptive modifier. Conversely, a factor that increases 
the contractile properties of the sarcomere or the downstream consequences of the 
sarcomere mutation and that adds additional cellular strain (e.g. by limiting energetics 
further) has the potential to be a disease-enhancing modifier.  
The importance of modifier genes cannot be overstated, as modifier genes can 
provide therapeutic avenues to prevent the onset of disease in many people carrying 
pathogenic mutations. As discussed (Chapter 1), knowledge of modifier genes and the 
factors that lead to their induction or suppression can lead to the identification of 
potential therapeutic regimens. Modifier genes are genes that can modify the 
expression of a disease-causal allele. This can be seen when variants in these genes -- 
knocking or changing the function of the protein -- have a demonstrable effect in 
disease expression. Mouse models may provide a setting for testing potential modifier 
genes. E.g., knock-out mice recaptitulate loss-of-function variants and provide an 
understanding of the basic properties of the gene. As Fhl1 is on the X chromosome, one 
hit is sufficient to affect its function in males. 
While we performed preliminary experiments to identify upstream factors that 
upregulate Fhl1 in HCM and assessed the role of estrogen signaling or serum response 
	   151	  
factor, such factors still remain elusive. Two possibilities appear to have potential for 
future investigation: Mef2 signaling [23] and DNA methylation [24].  
 Three future directions could be helpful for further elucidating disease processes 
discussed in this dissertation. One would be full identification of modifier genes by 
comparing DNA from individuals with deleterious sarcomere mutations who developed 
or did not develop HCM. In addition, this can be complemented with mixed background 
mouse models crossed with the sarcomere mutation. With the decreasing cost of 
exome and whole genome sequencing, this analysis will become possible in the near 
future. Second, high-throughput screens measuring changes in contractility can be 
performed to identify modifying factors. Predicting which factors may have modifying 
effects on contractility can be useful clinically [25]. Such an approach can be used to 
delineate the effect of multiple Fhl1 mutations. Also, additional screens can be 
conceived focusing on established critical downstream processes of the sarcomere 
mutation. Third, a mechanistic follow-up on Fhl1 can provide a real example of how a 
modifier gene can prevent disease pathology. The signals that affect Fhl1 expression in 
HCM can be investigated. This also provides a setting to assess whether a genetic 
modifier can prevent or reverse the onset of pathology by using in vivo overexpression 
techniques of the Fhl1 isoforms. 
 Future work might address the role of Fhl1 in disease while carefully examining 
the role of each isoform separately. For example, the role of the 16 amino-acid 
sequence on the N-terminus of the induced isoform can be assessed. Mice 
overexpressing both isoforms can be generated. These mice can be used to assess 
whether overexpression of Fhl1 can inhibit HCM further and whether the effects from 
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overexpressing either isoform differ. The 16 amino-acid sequence on the longer isoform 
is conserved between mouse and human, which should predict a physiologic function, 
i.e. a potential biochemical difference. In addition, such mouse models can be used to 
assess Fhl1 roles in other tissues and disease settings. Fhl1 may have distinct roles in 
the various tissues it is putatively expressed in, such as spleen, thymus, testis ovary, 
brain, placenta, lung, liver, kidney and pancreatic tissue [9], that could also be 
ascertained. 
 In addition, Fhl1 has nine zinc fingers with which it may be involved in 
biomechanical sensing and possibly in integrating multiple signals. Elucidating this 
further in the context of an overactive sarcomere and the two Fhl1 isoforms is possible 
by using biophysical models and by mutating key amino-acid substrates. As zinc fingers 
are important protein domains that mediate critical cellular interactions, such as protein-
protein or protein-nucleic acid, the presence of nine zinc fingers could potentially result 
in binding to a large number of proteins. Also, the combination of these domains on a 
single protein molecule may create a structural domain that may be functionally 
important in cardiovascular physiology.  
 Examining the role of Fhl1 in other cardiomyopathies for which mouse models 
exist might provide useful information. Such experiments may define the role of Fhl1 in 
other cardiomyopathies, providing a functional assessment of common and divergent 
processes. Biophysical experiments have shown that sarcomere mutations result in 
worsened contractile properties in Dilated Cardiomyopathy (DCM), which is the opposite 
compared to HCM [26]. This suggests that Fhl1 ablation may ameliorate DCM in that 
	   153	  
setting. However, it is unclear what the Fhl1 effect would be in other settings such as 
DCM resulting from a non-sarcomere mutation or in HCM-like cardiomyopathies. 
Increasing our understanding of the role of Fhl1 in cardiomyopathies and the 
involvement of Fhl1 in cardiac processes can provide additional mechanistic insights. 
Pathways that Fhl1 participates in can be dissected with transcriptional profiling using 
knock-out and possibly transgenic models. These pathways are likely to be affected in 
models of cardiomyopathy in similar and different ways. 
Future work exploring such avenues has the potential to address novel questions 
of clinical importance and to increase understanding of the role of differential isoform 
regulation in disease as well as in other disease settings. For example, assessment of 
the role of Fhl1 in other cardiomyopathies may provide a clinically/therapeutically 
meaningful axis for further categorizing and understanding cardiomyopathies. 
Combined with results from identifying other modifiers of cardiomyopathy, this can 
contribute to a multi-gene approach that can be used to silence disease pathology in 
multiple settings even when the causal mutation causes severe effects and cannot be 
targeted with other approaches. 
 This dissertation offers four methods to analyze the transcriptome and identifies 
Four-and-a-half LIM domains protein 1 as an adaptive modifier in HCM. Further 
identification of genetic modifiers and clarification of their exact mode of action, with 
Fhl1 providing such an early opportunity, can improve our understanding of the 
underlying mechanisms of cardiomyopathies and potentially reveal avenues to novel 
treatments. 
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APPENDIX 1: Supplemental text and figures 
 
Supplemental text: 
 
5’ RNA-seq  
Below we describe the steps to construct RNA-seq libraries that yield increased proportions of 
5’ end sequences and computational approaches to identify genes with altered transcriptional 
initiation.  We also provide an approach for obtaining data images from the UCSC browser that 
can be sorted for analyses (Appendix 3).  
 
Library preparation: 
The steps for construction of libraries from RNA with increased proportions of fragments from 5’ 
ends of genes (Supplemental Fig. 5.1) are adapted from published methodologies [1, 2] and 
notably do not include normalization or fragmentation. 
 
Step 1: Isolate RNA. Total RNA can be isolated with Trizol or column-based methods. Trizol 
has some recognized advantages such as it can isolate RNA molecules of a large size 
spectrum and results in a high yield of RNA amount. 
 
Step 2: Assess RNA quality.  Assay an aliquot of the transcriptome on a gel and assess quality 
of 18S and 28S using Bioanalyzer (Agilent) or the Tapestation (Agilent).  Broken RNAs will have 
artificial 5’ ends as RNA hydrolysis may also occur at defined places. In addition, broken RNA 
will result in loss of the real 5’ ends since selection is done from the 3’ end (Step 3). Libraries 
constructed from broken RNA will have diminished enrichment of reads at 5’ ends. 
 
Step 3: Perform two-rounds of selecting RNAs possessing poly-A tails by annealing them to 
poly-T oligos bound to beads (Invitrogen) so as to remove rRNA. After annealing the RNAs to 
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the poly-T-beads, wash unbound material, and then elute the polyA species by melting the 
annealed structures at high temperature. It is crucial that temperatures do not exceed 720C to 
avoid extensive RNA hydrolysis. After 2 rounds of polyA selection, the rRNA should be ~5% of 
total RNA. 
 
Step 4: Reverse transcribe (RT) mRNAs using random hexamers (Invitrogen). Be sure reaction 
is complete to reach 5’ ends. Random primers can be of any length. Large random primers (10-
20bp) can exhibit higher specificities during annealing. This can result in preference to 
transcribing low expressing species, as the primer pool annealing to high expressing species 
would be depleted. While offering such an advantage, using long random primers may skew the 
measurement of the distribution of transcripts stronger than shorter random primers.  
 
Step 5: Perform double-stranded DNA (dsDNA) synthesis by adding Pol I and RNA-se H to the 
reacted products from Step 4 and incubate overnight. It is vital that dsDNA synthesis be 
performed as completely as possible, as inefficiencies will result in loss of 5’ ends. Priming at 
the end of the fragment is needed to preserve the information at the 5’ end, from either 
hydrolyzed RNA fragments resulting from RNA-se H digestion or leftover random hexamer from 
Step 4. Incubating the reaction overnight may aid in completion of the reaction.The resulting 
dsDNA is a polar molecule with directional information. (Discussed further at Step 9.) 
 
Step 6: Perform end-repair. This step typically uses addition of enzymes such as polymerases 
and exonucleases serving to obtain dsDNA fragments with no overhangs. 
 
Step 7: Perform Adenosine addition at 3’ ends of both DNA strands and then ligate appropriate 
next-generation sequencing adapters. The adenosine overhangs at 3’ ends prevent self-ligation 
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of dsDNA fragments during adapter ligation. An excess of adapter dimers may further reduce 
self-ligation events. 
 
Step 8: Perform size selection by fractionating the DNA library in an agarose gel to excise a 
size of about ~150-400bp. This can be achieved by running an electrophoresis chamber manual 
or by using specialized equipment such as Pippin Prep (Sage science). 
 
Size selection allows for appropriate size molecules for next-generation sequencing and 
enriches fragments that resulted from annealing of random hexamers near the 5’ ends of 
transcripts.  Failure to optimally execute this step can result in substantial loss of the material. 
Increase in yield can be achieved by making thinner gels or with the Pippin Prep.  
 
Step 9: Perform a uniform amplification of the library with PCR. The number of cycles of the 
PCR should be carefully selected so that the reaction does not reach saturation, but yields 
sufficient material for next-generation sequencers. To achieve uniform amplification of all 
fragments, stop the reaction at the stage of exponential amplification. A qPCR amplification 
reaction mirroring final amplification conditions can be used to map the amplification of the 
library. Cycle numbers at the upper range of the exponential phase can be selected for the final 
amplification. Multiple parallel reactions can be used to provide the necessary amount for 
sequencing. Using the majority of the library material in this process is important to maximize 
the complexity of the library. Note that lower than optimal cycles will lead to insufficient material 
and higher than optimal cycles will skew the data and introduce sequencing errors (such as 
when the abundance of dNTP becomes limiting). 
 
A library constructed and sequenced with this approach contains directional information owing 
to the polarity of the cDNA molecule. Sequences will have one of two configurations: 1) when 
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the fragment is sequenced from the end that corresponds to the upstream part of the reference 
transcript, the resulting sequence preserves the same strand and direction of the reference 
transcript. 2) Conversely, when the fragment is sequenced from the end that corresponds to the 
3’ end of the reference transcript, the resulting sequence is in reverse/complement relationship 
with the reference transcript. This information provides a signature of 5’ end sites (Supplemental 
Fig. 5.2). 
 
Computational analysis: 
Gene/transcript definitions: Gene and transcript definitions are retrieved from the UCSC 
genome browser using the Table browser. Thus, UCSC transcript definitions that are assigned 
to RefSeq names are used and these definitions are further processed to obtain annotation 
tables. For example, to evaluate overall gene expression, all exons of isoforms for each gene 
are merged. A second annotation file is made that maintains the 5’ end locations of isoforms of 
genes to process 5’ end differences. 
 
Using these UCSC transcript definitions, we estimate that 8,000 of the 30,000 annotated mouse 
genes have at least one additional annotated 5’ end. The “count_5pr_isoforms.pl” is provided 
(Supplemental software package). 
 
Expression analysis: Normalize libraries to control for differences in sequencing depth.  For 
similar samples comparing total RNA, housekeeping genes are good reference points. For 
dissimilar samples, a TATA box binding protein gene Tbp can provide the reference gene. 
 
Reads at 5’ end regions are expected to correspond to actual transcript levels (1 read:1 
transcript relationship). The total reads derived from other regions of transcripts have a 
dependency on transcript length and possibly RNA structure. 
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A p-value is computed using Bayesian statistics [3] to compare the read numbers for a gene 
from two samples. This takes into account the number of reads as evidence and their relative 
proportion in the assessed population. When a library is well constructed, this p-value is an 
accurate reflection of the comparison of the RNA species from the original sample. 
 
Comparison of read-depth distributions at 5’ end regions:  Reads are first aligned to the 
genome and transcriptome. The read-depths at every base-pair position at 5’ regions of genes 
are retrieved and compared between samples one gene at a time, after  normalization to the 
respective total gene expression. This comparison calculates the fold of the normalized read-
depths and a p-value using the Bayesian statistic. An assessment of a shift in read distribution 
is made when the calculated fold exceeds a parametrically defined fold-threshold (3-fold is 
used), and the p-value is lower compared to a p-value threshold (0.01 is used). Thus, changes 
in start-site usage is defined by quantifying the instances at 5’ ends at which there is a change 
in distribution of reads on the gene locus. The sum of these instances is used as a score, it is 
tabulated for all genes, and it is interpreted as a positive signal that can recognize shifts in 
distribution in either direction. Genes with identified changes in distributions are queried visually 
on the UCSC browser or Integrative Genome Viewer (IGV) from highest to lowest score to 
visually identify the change in read-depth profiles and to assess whether these changes 
correspond to changes in 5’ end usage. Evidence from UCSC browser sources (ESTs, mRNA 
annotations, conservation of sequence, and aligned locations of transcripts identified in other 
species) can be used to support the recognition of unannotated 5’ ends.  
 
The Supplemental software package provides a strategy to retrieve data images from the UCSC 
browser, and for sorting and organization of image data. Obtaining the coordinates of 5’ regions 
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using the UCSC browser allows retrieval of information about aligned reads in an automatic 
approach for multiple genes and for assessment of significance. 
 
Data on 5’ end usage is best when there is sufficient sequencing, when the 5’ end uses a 
unique exon, and when the reads are distributed on the gene locus with a strong 5’ end 
distribution. When applied genome-wide, this can provide a new dimension of information for 
transcriptional data. 
 
 
Additional references: 
 
1. Wang, Z., Gerstein, M. & Snyder, M. RNA-Seq: a revolutionary tool for transcriptomics. 
Nature reviews. Genetics 10, 57-63 (2009). 
 
2. Christodoulou, D.C., Gorham, J.M., Herman, D.S. & Seidman, J.G. Construction of 
normalized RNA-seq libraries for next-generation sequencing using the crab duplex-specific 
nuclease. Current protocols in molecular biology / edited by Frederick M. Ausubel ... [et al.] 
Chapter 4, Unit4 12 (2011). 
 
3. Audic, S. & Claverie, J.M. The significance of digital gene expression profiles. Genome 
research 7, 986-995 (1997). 
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Supplemental Figure 5.1 cDNA library construction steps to enhance 5’ sequencing. Random 
priming near 5' ends of transcripts (red) results in the synthesis of smaller fragments that are 
selected for sequencing. 
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a.   
b.   
 
Supplemental Figure 5.2 Read depth and reads of first exons of Fhl1 of (a) bFhl1 and (b) 
sFhl1 isoforms. Reads from the transcript (+, blue) strand precede reads on complement (-, red) 
strand, and illustrate directional information at 5’ regions. 
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Supplemental Figure 5.3 High technical replication of RNAseq libraries. Log values (base 10) 
of normalized expression values from two biological replicate samples of wildtype heart tissue 
are shown (R=0.994). 
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Supplemental Figure 5.4 Comparison of RNA-seq with sequencing analysis of gene 
expression. The fold change (base 2) of gene expression that show agreement (first and third 
quadrants) or disagreement (second and fourth quadrants) between the two methods are 
plotted for all genes (a minimum of 10 reads was required).  Agreement was defined when both 
methods concurred that expression was increased or decreased by 1.5 fold, p-value 0.001. 
Disagreement was defined when gene expression was discordant by 1.5 fold, p-value 0.001. 
There is strong correlation between these methods R=0.9.  
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Supplemental Figure 5.5 Receiver operating characteristic (ROC) curve illustrating the 
performance of the altered 5’ start-site algorithm for genes with RNA-seq score of 20 or higher. 
The area under the curve (AUC) corresponds to a p-value of 1.07E-11. 
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Supplemental Figure 5.6 Primer design scheme for semi-quantitative 5’RACE. In the same 
reaction, the relative concentration of queried isoforms can be assessed. Red arrows indicate 
primers that correspond to the ligated adapter at the 5’ end (supplied by company). Black 
arrows indicate primers designed to correspond to shared sequences in different isoforms. 
 
 
 
 
 
 
Supplemental Figure 5.7 5’RACE validates Fhl1 5’ end changes using primers that correspond 
to a common downstream exon of the isoforms (Methods). Fragments (numbered) were 
sequenced and aligned to the genome with Blat (UCSC browser) and shown with RNA-seq 
data. Alignment of these products corresponds to RNA-seq reads. The same total RNA was 
used for 5’RACE and RNA-seq. 
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Supplemental Figure 5.8 Transcriptional profiles of isolated myocytes and non-
myocytes/fibroblasts were assessed with RNA-seq. Transcriptional switch of Fhl1 occurs in 
myocytes (red arrows) while isoform 2 is not expressed in non-myocytes (green arrows). 
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Supplemental Figure 5.9 Fhl1 expression in left ventricles tissue derived from wildtype, 
Fhl1LacZ/LacZ (Fhl1-null) , MHC403/+, MHC403/+/ Fhl1LacZ/LacZ .  The location of the inserted LacZ 
sequences is indicated (*). Note that no encoding Fhl1 exon sequences are absent while 5’ 
regulatory elements are expressed in Fhl1-null mice.  The LacZ sequences were detected by 
manual sequence assembly (not shown) and encode the protein in-frame. 
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APPENDIX 2: Published contributions4 
 
My main contribution for the work summarized below was the optimization of the RNA-
seq steps (as shown in Chapter 5) and the development and application of an automatic 
analysis workflow. For the Titin paper, I also performed verification of a Titin splice 
isoform that was originally visualized from RNA-seq data. For the micro-RNA study, I 
provided an initial analysis of the sequence data. I am very grateful to have had the 
opportunity to work with these researchers and to have been able to contribute to this 
work. 
 
 
Stable gene targeting in human cells using single-strand oligonucleotides with modified 
bases. Rios X, Briggs AW, Christodoulou D, Gorham JM, Seidman JG, Church GM. 
PLoS One. 2012;7(5):e36697. 
 
Abstract 
Recent advances allow multiplexed genome engineering in E. coli, employing easily 
designed oligonucleotides to edit multiple loci simultaneously. A similar technology in 
human cells would greatly expedite functional genomics, both by enhancing our ability 
to test how individual variants such as single nucleotide polymorphisms (SNPs) are 
related to specific phenotypes, and potentially allowing simultaneous mutation of 
multiple loci. However, oligo-mediated targeting of human cells is currently limited by 
low targeting efficiencies and low survival of modified cells. Using a HeLa-based EGFP-
rescue reporter system we show that use of modified base analogs can increase 
targeting efficiency, in part by avoiding the mismatch repair machinery. We investigate 
the effects of oligonucleotide toxicity and find a strong correlation between the number 
of phosphorothioate bonds and toxicity. Stably EGFP-corrected cells were generated at 
a frequency of ~0.05% with an optimized oligonucleotide design combining modified 
bases and reduced number of phosphorothioate bonds. We provide evidence from 
comparative RNA-seq analysis suggesting cellular immunity induced by the 
oligonucleotides might contribute to the low viability of oligo-corrected cells. Further 
optimization of this method should allow rapid and scalable genome engineering in 
human cells. 
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  Information	  obtained	  from	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Truncations of titin causing dilated cardiomyopathy. Herman DS, Lam L, Taylor MR, 
Wang L, Teekakirikul P, Christodoulou D, Conner L, DePalma SR, McDonough B, 
Sparks E, Teodorescu DL, Cirino AL, Banner NR, Pennell DJ, Graw S, Merlo M, Di 
Lenarda A, Sinagra G, Bos JM, Ackerman MJ, Mitchell RN, Murry CE, Lakdawala NK, 
Ho CY, Barton PJ, Cook SA, Mestroni L, Seidman JG, Seidman CE.vN Engl J Med. 
2012 Feb 16;366(7):619-28.  
 
Abstract: 
BACKGROUND: 
Dilated cardiomyopathy and hypertrophic cardiomyopathy arise from mutations in many 
genes. TTN, the gene encoding the sarcomere protein titin, has been insufficiently 
analyzed for cardiomyopathy mutations because of its enormous size. 
METHODS: 
We analyzed TTN in 312 subjects with dilated cardiomyopathy, 231 subjects with 
hypertrophic cardiomyopathy, and 249 controls by using next-generation or dideoxy 
sequencing. We evaluated deleterious variants for cosegregation in families and 
assessed clinical characteristics. 
RESULTS: 
We identified 72 unique mutations (25 nonsense, 23 frameshift, 23 splicing, and 1 large 
tandem insertion) that altered full-length titin. Among subjects studied by means of next-
generation sequencing, the frequency of TTN mutations was significantly higher among 
subjects with dilated cardiomyopathy (54 of 203 [27%]) than among subjects with 
hypertrophic cardiomyopathy (3 of 231 [1%], P=3×10(-16)) or controls (7 of 249 [3%], 
P=9×10(-14)). TTN mutations cosegregated with dilated cardiomyopathy in families 
(combined lod score, 11.1) with high (>95%) observed penetrance after the age of 40 
years. Mutations associated with dilated cardiomyopathy were overrepresented in the 
titin A-band but were absent from the Z-disk and M-band regions of titin (P≤0.01 for all 
comparisons). Overall, the rates of cardiac outcomes were similar in subjects with and 
those without TTN mutations, but adverse events occurred earlier in male mutation 
carriers than in female carriers (P=4×10(-5)). 
CONCLUSIONS: 
TTN truncating mutations are a common cause of dilated cardiomyopathy, occurring in 
approximately 25% of familial cases of idiopathic dilated cardiomyopathy and in 18% of 
sporadic cases. Incorporation of sequencing approaches that detect TTN truncations 
into genetic testing for dilated cardiomyopathy should substantially increase test 
sensitivity, thereby allowing earlier diagnosis and therapeutic intervention for many 
patients with dilated cardiomyopathy. Defining the functional effects of TTN truncating 
mutations should improve our understanding of the pathophysiology of dilated 
cardiomyopathy. (Funded by the Howard Hughes Medical Institute and others.). 
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Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for 
postnatal cardiac homeostasis. Delgado-Olguín P, Huang Y, Li X, Christodoulou D, 
Seidman CE, Seidman JG, Tarakhovsky A, Bruneau BG. Nat Genet. 2012 Jan 
22;44(3):343-7.  
 
Abstract 
Adult-onset diseases can be associated with in utero events, but mechanisms for this 
remain unknown(1,2). The Polycomb histone methyltransferase Ezh2 stabilizes 
transcription by depositing repressive marks during development that persist into 
adulthood(3-9), but its function in postnatal organ homeostasis is unknown. We show 
that Ezh2 stabilizes cardiac gene expression and prevents cardiac pathology by 
repressing the homeodomain transcription factor gene Six1, which functions in cardiac 
progenitor cells but is stably silenced upon cardiac differentiation. Deletion of Ezh2 in 
cardiac progenitors caused postnatal myocardial pathology and destabilized cardiac 
gene expression with activation of Six1-dependent skeletal muscle genes. Six1 induced 
cardiomyocyte hypertrophy and skeletal muscle gene expression. Furthermore, 
genetically reducing Six1 levels rescued the pathology of Ezh2-deficient hearts. Thus, 
Ezh2-mediated repression of Six1 in differentiating cardiac progenitors is essential for 
stable gene expression and homeostasis in the postnatal heart. Our results suggest that 
epigenetic dysregulation in embryonic progenitor cells is a predisposing factor for adult 
disease and dysregulated stress responses. 
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Polycomb repressive complex 2 regulates normal development of the mouse heart. He 
A, Ma Q, Cao J, von Gise A, Zhou P, Xie H, Zhang B, Hsing M, Christodoulou DC, 
Cahan P, Daley GQ, Kong SW, Orkin SH, Seidman CE, Seidman JG, Pu WT. Circ Res. 
2012 Feb 3;110(3):406-15. 
 
Abstract 
RATIONALE: 
Epigenetic marks are crucial for organogenesis, but their role in heart development is 
poorly understood. Polycomb repressive complex 2 (PRC2) trimethylates histone H3 at 
lysine 27, which establishes H3K27me3 repressive epigenetic marks that promote 
tissue-specific differentiation by silencing ectopic gene programs. 
OBJECTIVE: 
We studied the function of PRC2 in murine heart development using a tissue-restricted 
conditional inactivation strategy. 
METHODS AND RESULTS: 
Inactivation of the PRC2 subunit Ezh2 by Nkx2-5(Cre) (Ezh2(NK)) caused lethal 
congenital heart malformations, namely, compact myocardial hypoplasia, 
hypertrabeculation, and ventricular septal defect. Candidate and genome-wide RNA 
expression profiling and chromatin immunoprecipitation analyses of Ezh2(NK) heart 
identified genes directly repressed by EZH2. Among these were the potent cell cycle 
inhibitors Ink4a/b (inhibitors of cyclin-dependent kinase 4 A and B), the upregulation of 
which was associated with decreased cardiomyocyte proliferation in Ezh2(NK). EZH2-
repressed genes were enriched for transcriptional regulators of noncardiomyocyte 
expression programs such as Pax6, Isl1, and Six1. EZH2 was also required for proper 
spatiotemporal regulation of cardiac gene expression, because Hcn4, Mlc2a, and 
Bmp10 were inappropriately upregulated in ventricular RNA. PRC2 was also required 
later in heart development, as indicated by cardiomyocyte-restricted TNT-Cre 
inactivation of the PRC2 subunit Eed. However, Ezh2 inactivation by TNT-Cre did not 
cause an overt phenotype, likely because of functional redundancy with Ezh1. Thus, 
early Ezh2 inactivation by Nk2-5(Cre) caused later disruption of cardiomyocyte gene 
expression and heart development. 
CONCLUSIONS: 
Our study reveals a previously undescribed role of EZH2 in regulating heart formation 
and shows that perturbation of the epigenetic landscape early in cardiogenesis has 
sustained disruptive effects at later developmental stages. 
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Barcoding bias in high-throughput multiplex sequencing of miRNA. Alon S, Vigneault F, 
Eminaga S, Christodoulou DC, Seidman JG, Church GM, Eisenberg E. Genome Res. 
2011 Sep;21(9):1506-11.  
 
Abstract 
Second-generation sequencing is gradually becoming the method of choice for miRNA 
detection and expression profiling. Given the relatively small number of miRNAs and 
improvements in DNA sequencing technology, studying miRNA expression profiles of 
multiple samples in a single flow cell lane becomes feasible. Multiplexing strategies 
require marking each miRNA library with a DNA barcode. Here we report that barcodes 
introduced through adapter ligation confer significant bias on miRNA expression 
profiles. This bias is much higher than the expected Poisson noise and masks 
significant expression differences between miRNA libraries. This bias can be eliminated 
by adding barcodes during PCR amplification of libraries. The accuracy of miRNA 
expression measurement in multiplexed experiments becomes a function of sample 
number. 
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APPENDIX 3: Automatic download of data images from the UCSC 
browser 
 
This allows collection of data images using the UCSC genome browser platform which 
can be then be imported automatically and in the desired sorted order on Microsoft 
Powerpoint (Detailed instructions in README.txt file, Supplemental software package, 
Chapter 5: http://seidman.med.harvard.edu/fgs/software/RNAseq-5pr-package.tar.gz) 
 
 
Figure Appx. 3.1. Data browse mode using the UCSC genome browser 
(http://genome.ucsc.edu). The retrieved data image is shown in a green box. 
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Figure Appx. 3.2. Shown is image data imported on Microsoft powerpoint after the 
images were downloaded. 
 
 
Attributions: Danos Christodoulou and Steve DePalma co-developed this approach.  
